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Abstract 
Sickle cell disease (SCD) is a group of genetic disorder that occurs due to genetic mutation 
of a beta-globin gene that lead to production of pathogenic hemoglobin S (HB S). Genotypes of 
SCD include Hb SS (sickle cell anemia) which is the most common and severe form of SCD 
affects about 20 to 25 million people worldwide, HbSC, Hb Sβ+- thalassemia, and Hb Sβ0-
thalassemia. SCD is characterized by multiorgan complications that, in turn, affect lipids 
composition. During hypoxia a sequence of changes will take place such as HbS polymerization, 
erythrocyte rigidity and stickiness, and oxidative stress. The combination of these changes will 
affect lipids components such as polyunsaturated fatty acids (PUFA), which are substrates for a 
significant number of bioactive lipids such as the eicosanoids and some of the endocannabinoids. 
For example, vaso-occlusion crisis, the most common cause of SDC hospitalization, is found to 
be accompanied by changes in PUFA components of RBCs cell membrane encompassing 
Omega-3 and Omega-6. This comprehensive review outlines lipid changes that accompany SCD 
and also identify the gaps in our knowledge. This review will also allow us to devise better 
treatment options to manage the different pathophysiology and complications of SCD.  
Introduction 
1 Background 
Sickle cell disease (SCD) is a group of genetic disorders1,2. It is caused by genetic 
mutation in the beta-globin gene which results in the production of abnormal hemoglobin S (HbS), 
or the HbS trait 3. According to the World Health Organization (WHO), 20-25 million cases of 
global SCD are of the homozygous HbSS subtype. The vast majority of these cases are located 
in sub-Saharan Africa, accounting for approximately 12-15 million people, with India as a close 
second of nearly 5-10 million cases 4.  
The biochemical variations that accompany the SCD mutation are numerous. Among such 
variation are expected difference in the lipidome. Lipidomics is a field concerned with investigating 
the roles lipids have in various diseases; the primary functions of lipids include them serving as 
energy reservoirs, signaling molecules, and to compartmentalize (via membrane formation) 
various biochemical reactions5,6. Understanding the structures and functions of these molecules 
can allow for a better understanding of pathways that underly any given disease or injury. For 
example, the high oxidative stress caused by sickle cell disease may result in a high degree of 
oxidation of polyunsaturated fatty acids (PUFAs), which are substrates for a significant number of 
bioactive lipids such as the eicosanoids7. Despite more apparent metabolic modulations, the 
lipidome has not been studied in detail with respect to SCD. Here we outline what is known to 
date with regards to the lipid and metabolic changes that accompany SCD, and also identify the 
gaps in the current literature with respect to these topics. A better understanding of the lipid and 
metabolic changes accompanying SCD will allow us to devise better treatment options to manage 
the different pathophysiology of SCD. 
2 Pathophysiology 
At the molecular level, normal hemoglobin (Hb) consists of two α and two β chains 
genetically coded by genes on chromosomes 16 and 11. When a mutation occurs on 
chromosome 11, the nitrogen base adenine codon GAG) is substituted by thymine (GTG) leading 
to replacement of glutamic acid (hydrophilic) to valine (hydrophobic) in position 6 of the globin’s 
β chain n-terminal end. The ultimate result of this process is the formation of pathogenic HbS 8. 
During hypoxia, the deoxygenated HbS upregulates a long chain of insoluble polymers, causing 
rigidity and damage to the red blood cells (RBCs), resulting in the characteristic “sickle” shape.  
Furthermore, HbS gives RBCs a “sticky” property due to the secretion of adhesion molecules 
such as Integrin α4β1 which interact with endothelial cells’ membranes, altering the blood supply.  
Consequently, this affects the half-life of RBCs which is reduced to 10-20 days instead of 120 
days as is the half-life of normal RBCs 8–10.  
A series of changes occur due to the chromosome 11 mutation (Figure 1). During sickling, 
hemolysis occurs releasing free hemoglobin into the serum, which causes calcium pump 
dysfunction as RBCs obtain excess Na+ and Ca2+ ions with a loss of K+ ions and water. 
Additionally, nitric oxide (NO) production is inhibited due to hypoxia, enabling sickle cells to stick 
more readily to the endothelium. Moreover, the extracellular hemoglobin interacts with NO leading 
to decreased nitric oxide concentration in plasma and endothelial tissue, inducing vascular 
complications such as vasoconstriction8–10. 
 
Figure 1 – Pathophysiology of SCD: a: The β globin chain mutation encoded in chromosome 11 
results in substitution of adenine (GAG) by thymine (GTG), enabling the “sickled” erythrocyte. b: Under 
certain conditions such as those from environmental factors and hypoxia, Hbs is deoxygenated, causing 
long-chain polymerization which activates the sickling of erythrocyte. 
3 SCD Genotypes differentiation 
When a single copy HbS inherited from each of the parents leads to homozygous HbSS 
also known as sickle cell anemia which is a very common SCD disorder11,12. Coinheritance of 
HbS with other pathogenic hemoglobin forms results in heterozygous classes of SCD 12. 
Heterozygous genotypes include hemoglobin SC (HbSC) HbSβ+- thalassemia, HbSβ0-
thalassemia and other rare types as can be seen in Figure 2 4,8. 
 
Figure 2: Probability of gene inheritance in SCD: If each of the parents carries a single copy of 
pathogenic hemoglobin (HbAS, HbAC, HbSβ0, HbSβ+), the probability for children to inherit the disease 
as follows: 25% are affected (HbSS, HbSC, HbSβ0 , HbSβ+ ), 50% are carriers (HbAS, HbAC, HbSβ0, 
HbSβ+), and 25% are normal (HbAA). 
One of the main consequences of SCD is the onset of anemia. Anemia is caused by 
reduction in hemoglobin (Hb) concentration level. The short lifespan of RBCs in SCD, again 
approximately 10-to-20 days in contrast to 120 days for healthy individuals, causes a decreased 
number of RBCs and prompts a reduction in oxygen delivery to tissues (anemia). Hb in healthy 
individuals have either HbA, HbA2 and HbF genotypes, usually maintaining oxygen homeostasis 
throughout the body. However, sickle cell anemia (SCA) incurred by the inherited HbS gene is 
associated with different sub-genotypes: HbSS(Sickle Cell Anemia), HbSC, HbSβ0  thalassemia, 
HbSβ+ thalassemia, HbSα thalassemia, HbSD and HBAS (Sickle cell trait). The different 
genotypes, their respective phenotypes and prevalence are shown in Table 1. 
Table 1: SCD genotype, severity of complication, region, effected ethnicities, and percent of 
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Arab 
Very rare  
combinations and 
clinical symptoms  
and may develop  
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Very rare N/A  1,2,3,4,5 
1.Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease 
around the world. Paediatr Respir Rev. 2014;15(1):4-12. doi:10.1016/j.prrv.2013.11.003 
2.Habara A, Steinberg MH. Minireview: Genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med 
(Maywood). 2016;241(7):689-696. doi:10.1177/1535370216636726 
3.Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet. 2010;376(9757):2018-2031. 
doi:10.1016/S0140-6736(10)61029-X 
4-Hemoglobinopathy patterns - UpToDate. Accessed July 7, 2020. https://www-uptodate-
com.proxy.library.vcu.edu/contents/image?imageKey=HEME%2F116210&topicKey=HEME%2F7115&search=Overv
iew%20of%20variant%20sickle%20cell%20syndromes&rank=1~150&source=see_link 
5-Sickle cell trait - UpToDate. Accessed July 14, 2020. https://www-uptodate-
com.proxy.library.vcu.edu/contents/sickle-cell-
trait?search=Overview%20of%20variant%20sickle%20cell%20syndromes&topicRef=7115&source=see_link 
6-.Shanthala Devi AM, Rameshkumar K, Sitalakshmi S. Hb D: A Not So Rare Hemoglobinopathy. Indian J Hematol 
Blood Transfus. 2016;32(Suppl 1):294-298. doi:10.1007/s12288-013-0319-3 
 
4 Global burden of SCD:  
 Globally, SCD is common in countries where malaria is widespread 13. Annually, 275,000 
to 300,000 children are born with SDC about 75% to 85% of them occur in Africa (Table2) 13,14. 
However, these numbers are expected to reach 400,000 births/year by 2050 13. Regarding the 
survival rate, in developed countries, children with SDC survive to adolescence. Whereas, in 
developing countries, the mortality rate among children with SCD is higher. For example, in Africa, 
50% to 80% of children with SCD die before five years old of age and 16.5% in West Africa (Aygun 
& Odame, 2012). 
Table 2: Annual estimation of SCD patient according to WHO1 : 
Region Number 
African region 233,289 
American region 9,047 
Eastern Mediterranean region 6,491 
European region 1,292 
South–east Asian region 26,037 
Western Pacific region 13 
World 276,168 





Figure3: Number of newborns with SCA in 2010. The figure is reproduced using 15 data by R 
software version (3.6.3). 
5 SCD cell Disease in Saudi Arabia and the U.S 
SCD is one of the most prevalent genetic disorders in Saudi Arabia.  It was detected for 
the first time in the Eastern province in the 1960s. This discovery initiated multiple screening 
investigations across different regions of Saudi Arabia to determine the impact of SCD. The 
prevalence of SCD among the Saudi population is still not fully understood. However, the 
Premarital Screening Program (PSP) from 2004 to 2005 reported that nearly 4.2% of screened 
adults carried the HbS gene, or exhibited the SCD trait, and 0.26% of the total population had 
SCD. For thalassemia, 3.22% carried the trait and 0.07% were affected 16. Another study 
conducted in 2011 suggested that somewhere between 2% to 27% of the Saudi population carry 
SCD trait 17. Nonetheless, newborn screening for SCD is absent in Saudi Arabia and, therefore, 
the true prevalence is likely underestimated.  
In the U.S, the sickle cell trait (SCT) differs greatly across states, between different 
ethnicities and races. It is likely that many SCT carriers in the United States are not aware of their 
medical sickle cell condition due to the mildness of symptoms. Thus, the exact number of cases 
in the U.S is unspecified18. However, it has been estimated that roughly 100,000 American are 
affected with SCD 19. Additionally, approximately 15.5  out of every 1000 American births have 
been speculated to have SCD, of which the group with the highest prevalence were African 
Americans representing 73.1 cases per 1000 births 18.  In 2004, the average hospitalization with 
underlying SCD-related complications reached 83,149 with a cost of roughly $488 million 20. 
6 Clinical manifestation and complication of SCD  
SCD is pervasive by its multisystem effects that are a result of vaso-occlusion (VOC). 
These effects include acute pain crises and chronic complications. VOC occurs as a consequence 
of sickled RBCs and the short life cycle of erythrocytes. Damaged erythrocytes block the blood 
supply in small vessels leading to VOC and organ damage19. Although VOC’s acute pain crisis is 
the most common SCD complication that results in hospitalization21, chronic complications often 
come from VOC including cardiovascular, pulmonary, nervous, gastrointestinal, musculoskeletal, 
urogenital, spleen and systemic inflammation 19. These complications can vary across each 
patient, and could range from mild to severe problems 4. Even though some complications can 
be improved with current therapeutic interventions, such as pain crisis and leg ulcers, there is little 
to no evidence supporting the improvement in other more chronic, end-stage complications like 
renal dysfunction 4. 
The SCD complications' severity can varies among haplotypes and coinheritance of fetal 
hemoglobin (HbF) and α-thalassemia. HbF, found in newborns, has a higher affinity to carry 
oxygen than normal adult Hb α2β2; thus, SCD-related symptoms start to emerge after six months 
postpartum, when HbF levels decline. It has been demonstrated that individuals with homozygous 
SCD in the Saudi-Indian haplotype have a high level of HbF, exhibiting reduction in SCD 
complications as a result of the decrease in HbS polymerization rate. Another genetic modifier 
that impacts the manifestation of SCD complications is the coinheritance of α-thalassemia 4,22. 
Coinheritance of α-thalassemia incurs a reduction in the HbS polymerization rate, which leads to 
an increase in Hb concentration and the RBCs' lifespan 22. Also, it reduces hemolysis of RBCs 
leading to decrease in some complications like stroke and leg ulcers. Despite these advantages, 
∝ -thalassemia increases the progression of other complications such as pain crisis and acute 
chest syndrome 22. 
 
7 Method: 
We acquired the studies by searching in PubMed. In the beginning, we searched using two terms 
(sickle cell and lipidome), and we get only 9 publications. After that, we tried to expand our 
research terms by using the disease name, lipid types, and the complications of our interest. The 
detailed terms are represented in table 3. 
Table 3: Research terms used for the literature review: 
Database  Terms 
PubMed ((("sickle"[All Fields] OR "sickled"[All Fields] OR "sickles"[All Fields] OR "sickling"[All 
Fields]) AND ("cells"[MeSH Terms] OR "cells"[All Fields] OR "cell"[All Fields]) AND ("fatty 
acids"[MeSH Terms] OR ("fatty"[All Fields] AND "acids"[All Fields]) OR "fatty acids"[All 
Fields] OR ("glycerolipid"[All Fields] OR "glycerolipids"[All Fields]) OR 
("glycerophospholipids"[MeSH Terms] OR "glycerophospholipids"[All Fields] OR 
"glycerophospholipid"[All Fields]) OR ("sphingolipids"[MeSH Terms] OR 
"sphingolipids"[All Fields] OR "sphingolipid"[All Fields]) OR ("sterolic"[All Fields] OR 
"sterols"[MeSH Terms] OR "sterols"[All Fields] OR "sterol"[All Fields]) OR 
("prenol"[Supplementary Concept] OR "prenol"[All Fields] OR "prenols"[All Fields]) OR 
"saccharolipids"[All Fields] OR ("polyketides"[MeSH Terms] OR "polyketides"[All Fields] 
OR "polyketide"[All Fields])) AND ("acute chest syndrome"[MeSH Terms] OR ("acute"[All 
Fields] AND "chest"[All Fields] AND "syndrome"[All Fields]) OR "acute chest 
syndrome"[All Fields] OR ("vasoocclusion"[All Fields] OR "vasoocclusive"[All Fields]) OR 
"vaso-occlusive"[All Fields] OR ("vasoocclusion"[All Fields] OR "vasoocclusive"[All Fields]) 
OR "Vaso-occlusion"[All Fields] OR ("blood coagulation"[MeSH Terms] OR ("blood"[All 
Fields] AND "coagulation"[All Fields]) OR "blood coagulation"[All Fields]) OR 
("thrombin"[MeSH Terms] OR "thrombin"[All Fields] OR "thrombin s"[All Fields] OR 
"thrombine"[All Fields] OR "thrombins"[All Fields]) OR ("hypercoagulant"[All Fields] OR 
"hypercoagulative"[All Fields] OR "thrombophilia"[MeSH Terms] OR "thrombophilia"[All 
Fields] OR "hypercoagulability"[All Fields] OR "hypercoagulable"[All Fields] OR 
"hypercoagulation"[All Fields]))) NOT ("proteom"[All Fields] OR "proteome"[MeSH 
Terms] OR "proteome"[All Fields] OR "proteomes"[All Fields] OR "proteomical"[All Fields] 
OR "proteomically"[All Fields] OR "proteomics"[MeSH Terms] OR "proteomics"[All Fields] 
OR "proteomic"[All Fields] OR ("covid 19"[All Fields] OR "covid 19"[MeSH Terms] OR 
"covid 19 vaccines"[All Fields] OR "covid 19 vaccines"[MeSH Terms] OR "covid 19 
serotherapy"[All Fields] OR "covid 19 serotherapy"[Supplementary Concept] OR "covid 19 
nucleic acid testing"[All Fields] OR "covid 19 nucleic acid testing"[MeSH Terms] OR "covid 
19 serological testing"[All Fields] OR "covid 19 serological testing"[MeSH Terms] OR 
"covid 19 testing"[All Fields] OR "covid 19 testing"[MeSH Terms] OR "sars cov 2"[All 
Fields] OR "sars cov 2"[MeSH Terms] OR "severe acute respiratory syndrome coronavirus 
2"[All Fields] OR "ncov"[All Fields] OR "2019 ncov"[All Fields] OR (("coronavirus"[MeSH 
Terms] OR "coronavirus"[All Fields] OR "cov"[All Fields]) AND 
2019/11/01:3000/12/31[Date - Publication])) OR ("antibodie"[All Fields] OR 
"antibodies"[MeSH Terms] OR "antibodies"[All Fields] OR "antibody s"[All Fields] OR 
"antibodys"[All Fields] OR "immunoglobulins"[MeSH Terms] OR "immunoglobulins"[All 
Fields] OR "antibody"[All Fields]) OR ("protein s"[All Fields] OR "proteinous"[All Fields] 
























Figure: 4 PRISMA Flow Diagram. 
In PubMed, the search generated 33 articles. The duplicated and irrelevant articles were 
excluded. After that, the titles and abstracts were reviewed. The article that was investigated 
unapproved medications, evaluated types of oxidative stress compounds, and investigated a 
novel agent were excluded.  We also exclude articles that do not include lipid changes and 
evaluate unrelated complications. We searched for additional articles manually using “google 
scholar”. This search method is limited to lipids changes in sickle cell disease (not include the 
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8      Clinical manifestation and changes on lipidome in SCD 
 8.1 Pain and VOC  
VOC acute pain is the most common cause of SCD hospitalization 21. Pain episodes vary 
from one patient to another according to stress, physical, and physiological conditions 23,24. In 
SCD, the mechanism of pain is more complicated than the pain mechanisms in other diseases 
due to an involvement of multiple factors 21. These factors include HbS polymerization and 
adhesion molecules; HbS polymerization leads to RBC sickling, the release of inflammatory 
mediators, mast cell activation, and the release of endothelial factors; adhesion molecules, from 
both red and white blood cells 21,23,24. During the VOC pain crisis, the accumulation of inflammatory 
mediators leads to nociceptor activation23,24. For example, increased interleukin-1 (IL-1) is 
associated with elevated prostaglandins E2 (PGE2) and I2 (PGI2) synthesis which, in turn, causes 
nociceptor activation, inducing nerve fiber damage and pain 24. Prostaglandins  have also been 
found to affect signaling pathways that cause hyperalgesia -increase pain sensation- 25. The 
enzyme cyclooxygenase-2 (COX-2) converts fatty acid arachidonic acid (AA) to prostaglandin E2 
(PGE2), and oxidizes endocannabinoids 2-arachidonoylglycerol (2-AG) into prostaglandin 
glycerol esters (PG-Gs) and anandamide into prostaglandin ethanolamides (prostamides), 
respectively25. 
HbS polymerization affects the RBC membrane. In SCD, there is an elevation in 
phosphatidylserine (PS) expression both extra-and-intra-cellularly. According to van Tits et al. 
(2009), there is a greater increase in PS levels and coagulation factors during pain crises. PS 
contributes to VOC episodes through the activation of endothelial cells and causes adhesion of 
damaged (sickled) RBCs. In addition, secretory phospholipase A2 causes PS hydrolysis, which 
in turn leads to thromboxanes and prostaglandins generation, subsequently incurring the onset 
of acute chest syndrome ̶  the leading cause of SCD deaths 26. PS has a role in shortening the 
lifespan of RBCs. Besides PS, there are also changes in the polyunsaturated fatty acid (PUFA) 
components of RBCs’ cell membranes. Altered PUFAs include increase AA 20:4n-6, adrenic acid 
(22:4n-6), and osbond acid (22:5n-6) with decreased linoleic acid (LA, 18:2n-6), EPA (20:5n-3), 
and DHA (22:6n-3)27–29. These changes may participate in VOC by facilitating RBCs-endothelial 
interaction 29. Daak et al. demonstrated the efficacy of omega-3 fatty acid supplementation in 
HbSS patients, as they found a reduction of hospitalizations pertaining to SCD pain and VOC in 
patients that were administered EPA and DHA supplements 29. In addition, during VOC, there is 
an elevation in thromboxane B2 and 6-keto-prostaglandin F1α (6kPGF1α). This finding reflects the 
imbalance between vasoconstrictor and vasodilator in SCD patients 30. 
Opioids are the most commonly used analgesics for the management of both acute and 
chronic pain in SCD 23,31. Although morphine is the first-choice opioid for pain management in 
SCD, it causes mast cell activation 31, and this leads to hyperalgesia 23,31. In addition, morphine 
causes tolerance, respiratory depression, and nephropathy 23. In pain conditions not pertaining to 
SCD, persistent long-term opioid use leads to opioid receptors adaptation, efficacy reduction, and 
pronociceptive neurotransmitters activation (pronociceptive neurotransmitters have a contrary 
action of opioids analgesic effects). The neural adaptation to opioids is extremely complex and 
encompasses multiple pathways, such as activation of calcitonin gene-related peptide (CGRP) 
and neuropeptide substance P (sP), as well as downstream messengers derived from the 
aforementioned AA metabolism through cyclooxygenase (COX), lipoxygenase (LOX) and 
endocannabinoid pathways. During acute opioids treatment, sensory transmitters are inhibited, 
causing partial analgesia. In chronic opioids use, the secretion of CGRP and sP are increased; 
also, there is postsynaptic activation of CGRP, NK-1, N-methyl-d-aspartate (NMDA) receptors, 
coinciding with  the synthesis of PGs through cyclooxygenase pathways, and lipoxygenase 
metabolites (LT) through lipoxygenase pathways32. 
New strategies have been considered to reduce these side effects and increase efficacy 
by using adjuvant drugs or nutrients 33. One of these strategies involves combining morphine with 
omega-3 fatty acids 33,34. Omega-3 fatty acids such as EPA and DHA have anti-inflammatory and 
antinociceptive effects. This antinociceptive effect provides a new strategy to prevent and treat 
chronic pain in several diseases, and may improve the efficacy and reduce its side effects 33,34. A 
study conducted on male Wistar rats demonstrated analgesic and antinociceptive effects of 
omega-3 after 16 days of administration. In addition, using omega-3 fatty acid in combination with 
morphine induced the antinociceptive effect in both acute and chronic morphine use as well as 
reduction of tolerance in chronic morphine treatment. Furthermore, when used with omega-3 fatty 
acids, morphine’s analgesic effects were compounded despite administration with a sub-
therapeutic dose 34. The mechanism of omega-3 fatty acid supplementation producing 
antinociceptive is still poorly understood. However, it could be through (i) inhibition of the AA 
cascade, which leads to blocking the production of pro-inflammatory eicosanoids and cytokines, 
or (ii) through the production of E-series (RvE1, RvE2) and D-series (RvD1, RvD2) resolvins from 
EPA and DHA as precursors that have potent analgesic actions 33,34. This combinational therapy 
to our knowledge has not been tested in humans to treat SCD-linked pain and VOC. However, 
contrary to previous findings, Matte et al. (2019) evinced that using DHA in HbSS mice do not 
increase RvD1 level in plasma, eliciting the need for further study in the effects of omega 3 fatty 
acids35. 
The endocannabinoids system are another group of lipids that participate in pain 
regulation 36,37. Some studies have suggested that increased concentrations of endocannabinoids 
in the peripheral nervous system  leads to reduced hyperalgesia severity in chronic pain 37. A 
study conducted on HbSS-BERK sickle mice using inhibitor of fatty acid amid hydrolase (FAAH), 
URB597, lead to increased anandamide in the periphery by suppressing its degradation through 
inhibition of FAAH, the enzyme responsible for endogenous anandamide breakdown. That lead 
to decreased hyperalgesia and nociceptor sensitization via anandamide binding to CB1 receptor 
on the nociceptor terminal 37. Anandamide stimulates eryptosis at  concentrations of 2.5 μM; 
eryptosis is inherently enhanced in SCD mouse models 38. In SCD, eryptosis stimulation may lead 
to anemia 39. 
17R-resolvin D1 (17R-RvD1) is a novel promising therapeutic used to suppers 
inflammation related to SCD. A study conducted on humanized mice model assessed the 
impairment of specialized pro-resolving lipid mediators involving resolving-D1 (RvD1) and 17R-
RvD1 during hypoxia/reoxygenation 35 . In this in vivo model, coupled to an ex vivo model using 
SCD human blood, blood treated with RvD1 and 17R-RvD1 saw a reduction in the adhesion of 
leukocytes to tumor necrosis factor-a (TNF-a)–activated endothelial cells 35. This finding was 
validated in vivo by the HbSS mice model, which revealed the efficacy of both RvD1 and 17R-
RvD1 in diminishing leukocyte adhesion to the endothelial surface. This study also demonstrated 
the efficacy of administrating 17R-RvD1 in the reduction of neutrophil adhesion and 
transmigration in HbSS mice model 35. Since neutrophil adhesion preludes thrombus formation, 
which is considered the primary stage of VOC, prevention of neutrophil adhesion and 
transmigration will improve vaso-occlusion outcomes 35. 
8.2 Acute chest syndrome (ACS) 
Acute chest syndrome (ACS) is a life-threatening complication characterized by chest 
pain, fever, breathing difficulties, and pulmonary infiltrate which is apparent in pulmonary 
radiographs 40. It is the second most common cause of SCD patients’ hospitalization, and one of 
leading cause of patient’s death 40. ACS affects approximately 40% of SCD patients 41 and is the 
underlying cause for nearly 25% of SCD-related deaths 40. The main three causes of ACS are 
pulmonary infection, pulmonary embolization, and pulmonary infarction 42,43.  Indeed, pulmonary 
infection is considered the predominant cause of ACS 42. The National Acute Chest Syndrome 
Study assessed 671 ACS episodes for 538 SCD patients through the period of March 1993 to 
March 1997. The study found chlamydia infections is the most common cause for ACS episode 
in all age groups 44. However, Mycoplasma and viral pneumonia were most prevalent for ACS in 
young children 44. Besides infection, pulmonary embolism can induce ACS through infarcted bone 
marrow 43. Fat emboli is produced from infarcted bone marrow and travel throughout bloodstream 
to the lung and causes inflammation and ACS 43. In addition, pulmonary infarction participates in 
ACS development through adhesion of sickled RBCs to endothelial cells that leads to VOC and 
hypoxia 43. 
During fat embolism, secretory phospholipase A2 (sPLA2), a potent inflammatory 
mediator, is upregulated followed by inflammation 45. When the upregulated sPLA2 hydrolyses 
phospholipids into FFA and lysophospholipids, it generates inflammatory mediators including AA. 
As a consequence, AA produces farther inflammatory products that encompass thromboxane, 
leukotrienes, and prostaglandins 45,46. Therefore, the remarkable elevation of sPLA2 before 24-
48 hours of ACS could predict the episodes earlier in SCD patients 45. 
Lipid peroxidation also play a key role in ACS mechanism. AA undergo peroxidation 
through noncyclooxygenase pathway to produce F2 isoprostane. A study was conducted on 
HbSS and HbSC patients to assess the level of F2 isoprostanes in patients’ plasma during 
baseline, VOC and ACS. The study found a dramatic elevation (9-fold) of F2 isoprostanes 
concentration compared to normal volunteer and 6-fold increase compared to VOC41. In addition, 
F2 isoprostanes level declined after blood transfusion by 50-85%. However, transfusion leads to 
the incidence of bone marrow transplant rejection which is the only treatment for SCD47. 
 
8.3 Hyper-coagulopathy and SCD 
Coagulation activation is a common phenomenon in SCD. Markers of platelet activation 
can be found in SCD patients, suggesting a constant hypercoagulable state. In a study of SCD 
patients with PHT, Ataga et al found evidence of thrombin generation by detecting elevation of 
markers such as high fibrin degradation product, D-dimer, Thrombin–antithrombin complex (TAT) 
and prothrombin fragment 1.2 (F1+2) levels, that were higher in SCD patients than control, 
although not statistically significant. In addition, it was found that there were high levels of markers 
for platelet and endothelial activation, such sCD40L and sVCAM-1, respectively. These results 
indicate the intrinsic association of coagulation activation and endothelial dysfunction in SCD 48. 
Elevated plasma levels of fibrinogen and whole-blood viscosity in SCD patients are also 
suggestive of a state of hypercoagulability. These markers have been associated with the pain 
crisis, suggesting a role of increased fibrinogen-mediated platelet aggregation in blood viscosity 
during pain crises in SCD patients 49. This relationship was also reported by Tomer et al illustrating 
that pain episodes were associated with an elevation of plasma levels of F1+2, TAT, and D-dimer. 
They also demonstrated that frequency of pain episodes is correlated platelet procoagulant 
activity and plasma fibrinolytic activity 50. 
One of the main phospholipids involved in activation of coagulation is platelet activating 
factor (PAF). It is an acetyl-glyceryl-ether-phosphorylcholine that participates in the activation of 
many cells such platelets, endothelial cells, neutrophils, monocytes, and macrophages. In 
normal conditions, it is continuously produced in low quantities by the activity of PAF 
acetylhydrolases 51. The involvement of PAF in SCD has been demonstrated in several studies. 
For example, Oh et al. found high level of endogenous PAF in the plasma of patients with SCD 
when compared with normal volunteers, and suggested that higher circulating level of PAF in 
patients with SCD during steady state may play a role in maintaining a state of inflammation and 
circulatory stress in microcirculation. In this study, it was also demonstrated that high levels of 
PAF were not caused by attenuation of PAF catabolism. Interestingly, they found that platelets 
are not the major source of circulating PAF and suggested that the higher plasma level of PAF 
results from the abnormal interaction of neutrophils and vascular endothelium with sickle RBCs 
52.  
There is evidence that the synthesis of PAF by human polymorphonuclear cells (PMN) 
and endothelial cells could be modulated by nitric oxide (NO) levels. Mariano et al demonstrated 
that blockade of NO synthesis triggers a spontaneous production of PAF by endothelium 
and PMN cells, enhancing  PAF’ synthesis induced by TNF-α and LPS 53. In general, synthesis 
of NO promotes vasodilatation and inhibits platelet activation, aggregation and endothelial 
adhesion. However, NO inactivation by cell-free plasma Hb produced by hemolysis can block the 
NO effect on platelets. Therefore, the interaction between hemolysis, impaired NO bioavailability, 
and platelet activation might contribute to thrombosis and PHT in SCD 54. It has been suggested 
that SCD’ patients have decreased NO reserves, probably due to  low plasma levels of L-arginine 
(the precursor to NO), particularly during VOC, and these levels are inversely correlated with pain 
symptoms55. The authors propose that the three major mechanisms of impaired NO bioavailability 
are decreased plasma L-arginine, consumption of NO by cell-free plasma hemoglobin, and 
depletion by reactive oxygen species. 
A literature review on patients with SCD reported that chronically elevated PMN counts in 
SCD are associated with higher risk of sickle cells complication and mortality, suggesting a 
constant pro-inflammatory state even in the absence of an acute crisis 56. Moreover, the review 
also reported a higher than normal presence of PMNs in the pulmonary microcirculation at the 
capillary–tissue interface in SCD patients. The importance of leukocyte-intermediated 
inflammation in SCD has also been reported. A study in isolated perfused lungs evinced that the 
release of PAF and leukotriene (LTB4) from the activated PMN increased retention/adherence of 
sickled RBC. The authors argue that both PAF and LTB4 can influence vascular permeability, cell 
infiltration, and PMN adhesion to vascular endothelium by causing the release of other 
inflammatory mediators 57.  
Other mechanisms occurring in the membrane of sickled RBC could have the potential to 
exacerbate the pro-coagulation state in the disease pathology. As covered previously, studies 
assessing the roles of erythrocyte adhesion markers in patients with SCD demonstrate that 
erythrocyte PS exposure in the outer side of the cell membrane is a major determinant of RBC–
endothelial adhesion 58. The authors suggest that this loss of phospholipid asymmetry could 
participate in SCD vaso-occlusion. Therefore, the phenomenon of PS exposure in sickled red 
cells could aggravate the sickle cell anemia due to enhanced activation of coagulation. This PS 
exposure could also provide a negatively charged surface in RBCs facilitating the clotting cascade 
components contact. A study of blood from sickle cell patients demonstrated that PS positive’ 
RBC are positively correlated with plasma levels of F1+2, D-dimers, and plasmin-antiplasmin 
complex, suggesting that sickle RBCs are responsible to the hypercoagulable state in SCD 59. 
An important pro-coagulant phenomenon in SCD is the osmotic RBC shrinkage due to 
changes on the Hb effects on osmotic pressure. The kinetic loss of osmotic pressure of sickle-
cell Hb is caused by deoxygenation that dehydrate the erythrocyte and promote Hb aggregation 
60. Osmotic erythrocyte shrinkage can activate cation channels with subsequent Ca2+ influx and 
stimulation of sphingomyelinase to increase production of ceramides. Ca2+ and ceramide in 
sickled RBC are involved in change of phosphatidylserine asymmetry of the cell membrane. 
These mechanisms are also linked to the observation that PAF is released from erythrocytes 
triggered by hyperosmotic cell shrinkage. Lang et al showed that PAF in erythrocytes binds to 
PAFr and stimulates the breakdown of sphingomyelin with consequent production of ceramide, 
and that PAF activates cell shrinkage and PS exposure in the external membrane 61. 
An indirect consequence of high PAF production in SCD patients is the over-expression 
of platelet-activating factor receptor (PAFr), and its relationship with an increased chance of 
bacterial infection. PAFr is a G protein–coupled receptor of the lipid chemokine PAF. The role that 
PAFr plays in pneumococcal invasion has been established in vitro and in mice’ models of SCD. 
The proposed mechanism is that the phosphorylcholine on the pneumococcal cell wall mimics 
PAF and binds the bacteria to the endothelial cell membrane and also serves to insert the bacteria 
into the cell through PAFr uptake pathway 62. 
9 Treatments 
         9.1 Hydroxyurea 
The first discovery of Hydroxyurea was in 1869 by Dresler and Stein. In 1967, it was 
approved by the FDA as an antineoplastic agent to treat several types of tumors and leukemias. 
Decades later, it showed efficacy in the production of fetal Hb in SCD patients 63. For that, the 
FDA approved it as the first medication for SCD treatment in 1998 64. Hydroxyurea, a 
ribonucleotide reductase inhibitor, 65 leads to limiting the transformation of ribonucleosides into 
deoxyribonucleosides (the DNA building unit) which causes less DNA production 66 which in turn 
impacts erythropoiesis process 67. Consequently, stress hematopoiesis is prompted leading to 
recruitment of early erythroid progenitor cells that have ability to produce HbF 67; however this 
mechanism remains to be fully understood 68. In the term of disease outcomes, Hydroxyurea 
reduces the frequency of SCD complications such as VOC pain by about 50% as well as ACS 
and stroke 19,66. Besides, it inhibits WBC and reticulocytes' production that acts as inflammatory 
mediators and reduces the frequency of blood transfusion by 50% 66. In children with SCD, it 
shows clinical efficacy in minimizing the painful crisis, organ damage and stroke. Also, it enhances 
the growth and development of SCD children. The side effects of hydroxyurea are mild, and it 
mainly include nausea, headache, reticulocytopenia and neutropenia. Severe side effects are rare 
and may include cytopenia 66. 
9.2 L-glutamine 
 SCD patients demonstrate impairment in nicotinamide adenine dinucleotide (NAD) 
metabolism with decrease of the reduced NAD (NADH)  to NAD ratio leading to NAD redox 
potential depletion 65. In 2017, FDA approved L-glutamine for children and adults with SCA 69. It 
improves the NADH:NAD ratio resulting in enhancement NAD redox potential 65. Thus, it prevents 
erythrocytes sickling by the inhibition of oxidative stress, namely by its protective properties 
against free radicals. Also, it has been demonstrated to prevent other complications including 
VOC pain and reduce patient’s hospitalization 69. The therapy’s side effects include 
gastrointestinal effects accompanied by headache. However, hepatic and renal functions need to 
be further studied during medication course69. 
         9.3 Bone marrow transplant 
Bone marrow transplant is currently the only cure for SCD70. Although the cure rate is 
more than 80%, this procedure is limited among patients due to the lack of appropriate donors, 
and the severe side effects brought on by the procedure itself 70. Hematopoietic cell 
transplantation (HCT) outcomes are influenced by patients’ condition and SCD complications. In 
young patient with B-thalassemia and low risk disease the survival rate shown to be 93% and the 
disease-free survival rate is 91%. These percentages are worsened in high risk patients and could 
reach 79% for survival rate and 58% for disease-free survival in sever risk patients 71. 
However, HCT outcomes are influenced by several factors. Mainly, graft-versus-host 
disease (GVHD) causes HCT failure which promotes organ damage and death 71. Besides, some 
cases reported a delay in sexual organ development after HCT but the evidence was insufficient 
72.   
9.4 Emergency management 
 9.4.1 VOC management: 
The new clinical evidence of the complication management cause elevation in survival 
rate of patients with acute complications. Multiple institutions published a guideline algorithms to 
facilitate management of acute pain due to VOC such as National Heart, Lung and Blood 
Institution (NHLBI) 73. The complex pathophysiology of VOC causes a complexity of the 
management of the crisis 74. Basically, opioids are widely used in acute VOC pain management 
73. Guidelines recommended intravenous (IV) or subcutaneous morphine (dose 0.1-0.15 mg/kg) 
within 15 to 20 minutes of patients arrival in emergency department 75. According to NHLBI 
recommendations, administration of adjuvants medications beside opiates such as sedative and 
antihistamine 73. Also, NHLBI and other guidelines recommended further treatment for patients 
with inadequate pain relief 73. Oral pain control medications with comparable potency of IV 
medications must be prescribed to discharged patients 73. Guidelines also recommended the 
administration of oxygen to maintain oxygen saturation more than 92% 73. 
9.4.2 ACS management:  
Before treatment of ACS, patient assessment is required. X- ray should be obtained to 
assess the presence of new infiltrate. Usually the upper or middle lungs lobe affected in pediatric 
patients while the lower lobe is impacted in adult 73. The etiology of ACS includes infection (viral 
or bacterial) and embolism. The recommended management of ACS involves administration of 
broad-spectrum antibiotics and oxygen (O2 saturation more than 95%).  Also, blood transfusion 
may be required if the Hb level less than baseline level by 1.0 g/dl to improve O2 capacity 74.  
10 Discussion and future directions 
 SCD is characterized by severe complications that could be life-threatening such as VOC 
and hemolysis. A summary of the SCD complications is described in Table 3. The severity of 
complications ranges from patient to patient with regard to the disease phenotype and 
environmental factors. This review discussed the lipidomic changes of SCD for some complication 
as they are presently understood. However, there is a limited number of studies regarding 
lipidomics modulations in SCD, and the majority of them discuss only the HbSS type.  In addition, 
there are limited studies that examine the lipid changes pre and post medications use.  Morphine 
is widely used to manage VOC pain. However, due to its associated complications, new strategies 
have been used to reduce its side effects. Concomitant use of omega-3 fatty acids provides 
antinociceptive effects and increases morphine efficacy even in sub-therapeutic dosing. 
Resolvins and endocannabinoids systems are also being explored as therapeutics to target and 
manage pain in SCD. 
Table 4: Complications of SCD and a summary of the main characteristics. 
Complications  Characteristics 
Acute pain ● The most common reason for hospitalization. 
● Affects teenagers more than adults. 
●  May cause early death due to pain severity. 
● Occurs in HbSS more than HbSC 
● Its frequency decreases with high Hb F concentration. 
● Managed by using opiates.  
Infection ● Occurs mainly in children. 
● It is due to spleen impairment, micronutrients deficiency and 
complement activation deficiency. 
● S pneumoniae, H influenza, and non-typhi Salmonella species are 
the most frequent infections. 
● Prevented by using penicillin prophylaxis and immunization. 
Neurological complications ● Occurs due to vasculopathy. 
● The most common cause of stroke in pediatric is HbSS. 
● Stroke occurs as a result of blood flow dysregulation. 
● 90% of stroke risk could be reduced by blood transfusion. 
● Neurocognitive problems may be seen in children. 
● Intracranial bleeding is more frequent in adults. 
Acute chest syndrome ● The second leading cause of hospitalization. 
● Cause acute lungs injury. 
●  13% of cases need mechanical ventilation. 
● Managed by using broad-spectrum antibiotics,  
bronchodilators, and oxygen. 
Heart disease 
● Involve both diastolic and systolic dysfunctions. 
● Increase mortality rate. 
● 13% of SCD patients have left-side heart disease. 
Renal complications ● In SCD patients, partial oxygen and pH decrease with an increase 
in osmolality in the kidneys. That leads to an increase in HbS 
polymerization. 
●  Renal infarction occurs due to vaso-occlusion. 
● Early age renal dysfunction and albuminuria may occur.  
Hemolysis ● Most severe in HbSS phenotype. 
● Occurs because NO reduction. 
● Leads to other complications such as chronic anemia and PHT. 
Hyper-coagulopathy ● Elevation of coagulation markers in SCD patients even in steady 
state. 
● Leads to other complications such as venous thromboembolism, 
ACS, PHT and stroke. 
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Abstract:  
Introduction: A common risk factor for infertility is obesity. The global rise of obesity 
accompanied with infertility has led to widespread adoption of assisted reproductive 
technologies such as in vitro fertilization (IVF) to achieve pregnancy. However, pregnancy 
outcomes such as embryo quality vary after IVF, possibly due to disruptions in 
metabolism. Previous metabolomic studies investigating embryo quality were limited to 
characterizing broadly lipid classes, or a few molecular lipid species. Here, we sought to 
determine specific circulating lipids and metabolites with matrix-specific effects that could 
serve as putative biomarkers of embryo quality, correlated with BMI, and predicted clinical 
pregnancy subsequent IVF.  
Methods: Electronic health record (EHR) data, as well as lipids and metabolites obtained 
from follicular fluid (FF) and platelet poor plasma (PPP), were collected from women (n = 
26) undergoing IVF. Lipids and metabolites were acquired via untargeted mass 
spectrometry. For embryo quality and BMI, we performed multiple linear regression 
analysis to find correlates. For 6 weeks pregnancy, we applied a linear discriminant 
analysis to select lipids and metabolites that allowed for group determination.  
Results: Several lipids and metabolites were selected from both matrices (FF and PPP) 
that either outperformed models containing only EHR or added value to EHR models. In 
predicting embryo quality, glycerophospholipids obtained from PPP produced the best fit 
model. The predicted values include  (LPC) 22:6 , phosphatidylcholine (PC) 16:1/22:6, 
and  phosphatidylethanolamine-plasmalogen (PE-P) 16:0/22:6 were negatively 
correlated with 2PN while Phosphatidylethanolamine (PE) 18:0/20:3, 
lysophosphatidylethanolamine (LPE) 18:1, PC 14:0/16:1, and PE-P 16:0/20:5 were 
positively correlated with 2PN (R adjusted = 0.730, RMSE = 0.329). For rLDA of 6-weeks 
of pregnancy, the best model was the metabolite model obtained from Platelet Poor 
Plasma (misclassification = 3.85%, Entropy R-squared = 0.809). 
The BMI multicomponent domain model obtained from FF,  LPC 18:1, PC 16:1/22:6, and 
malic acid were negatively associated with BMI while Fasting insulin and PC 16:0/22:4 
were positively correlated with BMI values (R-square adjusted = 0.819, RMSE = 0.127). 
However, the combined data model for FF has the best prediction of BMI values. In this 
model, PE-P 16:0/22:6, aspartic acid, and fasting insulin as positively correlated variables 
with BMI values, whereas indole-3-propionic acid was negatively correlated with BMI (R-
squared adjusted = 0.856, RMSE = 0.113). 
Conclusion: High BMI is known to have detrimental effects on the development and 
success of pregnancy. It is also known to disrupt the endocrine pathways involved in the 
pregnancy process. This study provides information about metabolic signatures 
associated with BMI and pregnancy outcomes. Also, it shows the effect of 2PN value on 
embryo quality and the success of pregnancy. 
 
Introduction 
Infertility is a medical condition characterized by the inability of a couple to achieve 
clinical pregnancy after 12 months of regular, unprotected sexual intercourse. The 
prevalence of infertility for women of reproductive age is estimated to be 1 in every 7 
couples, and 1 in every 4 couples, for those within Western countries and economically 
developing countries respectively76. Although the strongest negative predictor of fertility 
is increasing age for women, it is believed that other risk factors such as lifestyle and 
environmental factors contribute significantly towards the development of infertility76. 
A common risk factor for infertility is obesity, a disorder that is estimated to affect 
42.1% of women, within the United States alone, who are 20 years of age or older77. 
Obesity is defined as a body mass index (BMI) ≥30 kg/m2, characterized by excessive 
adiposity78. Not only does obesity increase time to conception79, it increases the relative 
risk of chronic anovulation80, decreases the chance of spontaneous conception81, and is 
linked with greater odds of miscarriage82. A global rise in the prevalence of obesity in 
tandem with infertility has led to an increasing number of women to utilize assisted 
reproductive technologies such as in vitro fertilization (IVF) to achieve pregnancy83. 
However, women who are obese exhibit low responses to controlled ovarian stimulation 
via IVF84,85. Cellular and subcellular disruptions co-occurring with obesity may account 
for these poor reproductive outcomes subsequent to IVF.  
The impact of obesity on reproductive function can be understood through aberrant 
endocrine signaling pathways that dysregulate the hypothalamic-pituitary-ovarian (HPO) 
axis, the system that drives reproduction by cyclic production of gonadotropic and steroid 
hormones86. Notably, obesity exerts an inhibitory effect on gonadotropic production, and 
women who are obese require higher doses of administered gonadotropins such as 
follicle stimulating hormone (FSH) during IVF in order to achieve an ovulatory response, 
comparable to women of normal weights87,88. Women who are obese additionally have 
markedly lower pulsatile luteinizing hormone (LH) amplitudes and progesterone 
metabolite secretion, further implicating the HPO axis as a central mechanism for poor 
IVF outcomes89. Bridging obesity with the dysregulation of the HPO axis in women who 
are obese is insulin resistance (IR), which is exacerbated by lipotoxicity90,91.  
Lipotoxicity in ovarian tissues can exacerbate IR, is a potential mechanism for 
oocyte organelle damage, and has the potential to induce hyperinsulinemia, which can 
promote obesity92,93. Under euglycemic, hyperinsulinemia conditions, elevated non-
esterified fatty acid (FFA) content concomitant high insulin levels can selectively impair 
LH and FSH, suggesting that the endocrine disruption in women who are obese may be 
mediated by direct lipotoxic effects on the HPO axis94. During IVF, concentrations of FFA, 
triglyceride (TAG), and long-chain acylcarnitine species within follicular fluid (FF) of 
women who are obese are positively correlated with gonadotropin-stimulated androgen 
levels95. Additionally, in the FF of women with normal BMI who failed to respond to IVF, 
there is a significant shift in the accumulation of monoacylglycerols (MAG) and 
glycerophospholipids like phosphatidylethanolamine (PE) towards triacylglycerols (TAG) 
and cholesteryl esters96. Lastly, circulating levels of TAG as a total lipid class is negatively 
correlated with embryo quality, as determined by the presence of two clearly distinct 
pronuclei and two polar bodies (2PN)97. Taken together, a diversity of lipids and 
metabolites dysregulated in an obese state promote a number of deleterious 
pathophysiological processes, and exert modulatory effects on fertility.  
Yet which lipid species and metabolites are clinically relevant towards the 
predicting the outcomes of IVF in women who are obese remains unknown. Current 
clinical evidence for IVF success or failure have been methodologically limited to only a 
few lipid species studied, or do not associate specific lipid species with embryo quality or 
fertility, only assessing lipids by their classes (i.e. total TAG). Therefore, we sought to 
determine specific circulating lipids and metabolites, within the plasma and FF, that could 
serve as putative biomarkers of 2PN, and which play a role in reduced IVF pregnancy 
rates associated with obesity.  
Materials and Methods 
1) Patients 
Follicular fluid (FF), platelet poor plasma (PPP), and electronic health record (EHR) 
data were collected from women (n = 26) undergoing IVF. Body composition (percentage 
of body fat mass) was obtained by bioelectrical impedance98. Women’s weights were 
recorded as either normal, overweight, or obese. The study design has been previously 
reported (VCU IRB#: HM20004988), but in brief; starting on menstrual cycle day 3, 
patients self-administered gonadotropins and underwent transvaginal ultrasounds every 
2 days. Blood was drawn prior to ovarian stimulation via subcutaneous injection with 
human chorionic gonadotropin (hCG, 250 µg), and processed into plasma, once adequate 
mature follicles were detected (approximately cycle day 10-12). A follow-up visit coincided 
34-36 hours post hCG, where blood was drawn and FF was obtained during egg retrieval. 
Patients were asked to fast after midnight of the night before the baseline visit, and were 
provided an optional 2-hour oral glucose tolerance test to determine if they were diabetic 
(GDM threshold was ≥140 Mg/dl)99. Additionally, patients were asked to recall what they 
had eaten within the previous 24 hours prior to their follow-up visit. Whether or not 
pregnancy was achieved 6 weeks after IVF was recorded. Two weeks after oocyte 
retrieval, serum hCG was used to evaluate pregnancy and, if serum hCG was positive, 
an additional visit 6-weeks post hCG occurred to confirm absence or presence of 
pregnancy.  
2) Sample Preparation and Storage 
During egg retrieval, discarded FF was obtained and transferred to Heathrow 2.0 mL 
Screw-Top Tubes with O-Ring caps. Samples of FF were then stored at -80°C until 
needed for lipidomic and metabolomic analysis. 
The following protocol was used to prepare PPP: whole blood (7.4 mL) was collected 
in K2EDTA tubes upon the patient’s visit. Whole blood was then centrifuged at 1300g for 
10 minutes using an Eppendorf centrifuge 5810 R to separate the platelet rich plasma 
(PRP) layer. The upper PRP layer was then collected, avoiding contamination of the buffy 
coat. To obtain PPP, PRP was centrifuged at 2000 g for 15 minutes. Samples of PPP 
were then aliquoted at 0.2mL into Eppendorf tubes and stored at -80°C until needed for 
lipidomic and metabolomic analysis100. 
3) Lipidomic and Metabolomic Extraction 
3a) Extraction of lipids and metabolites for liquid chromatography (LC) lipidomic 
and metabolomic analysis 
Either 20 µL aliquot of FF or PPP had their lipids, along with water-soluble 
metabolites, extracted by a biphasic solvent system26. In detail, sample was introduced 
to 225 µL of cold methanol in a 1.5 mL polypropylene tube, mixed with odd chain and 
deuterated lipid internal standards [lysophosphatidylethanolamine (lysoPE 17:1), 
lysophosphatidylcholine (lysoPC 17:0), phosphatidylethanolamine (PE 17:0/17:0), 
phosphatidylcholine (PC 12:0/13:0), phosphatidylglycerol (PG 17:0/17:0), sphingosine 
(d17:1), d7 cholesterol, sphingomyelin (SM 17:0), C17-ceramide (d18:1/17:0), d3-palmitic 
acid (16:0/16:0/16:0), 1-margaroyl-glycerol (MAG 17:0/0:0/0:0), 1-oleoyl-2-acetyl-sn-
glycerol (DAG 18:1/2:0/0:0), 1,2-diacyl-sn-glycerol (DAG 12:0/12:0/0:0), and 1,3(d5)-
diheptadecanoyl-2-(10Z-heptadecenoyl)-glycerol (d5-TAG 17:0/17:1/17:0)]. Thereafter 
750 µL of cold methyl tert-butyl ether (MTBE) was added and vortexed, and phase 
separation induced by 188 µL of liquid chromatography mass spectrometry (LC-MS)-
grade water. Extracts were centrifuged at 12,300 rpm for 2 minutes, with the upper 
organic phase (300µL) collected for analysis of lipids, and evaporated under vacuum 
conditions. Resuspension occurred with 110µL of methanol/toluene (9:1, v/v) containing 
12-[(cyclohexylamino) carbonyl]amino]-dodecanoic acid (CUDA, 50 ng/ml; internal 
standard for quality control of injection), vortexed, and centrifuged at 800 rpm for 5 
minutes. The resultant supernatant (100µL) underwent lipidomic analysis. An aliquot 
(125µL) of the lower phase was evaporated under vacuum conditions and resuspended 
in pure acetonitrile (ACN). These extracted metabolites were then subjected to 
metabolomic acquisition via hydrophilic interaction (HILIC) LC-MS/MS101.  
3b) Extraction of metabolites for gas chromatography (GC) metabolomic analysis 
Small metabolites (<650 Daltons) were acquired from 30μl aliquots of FF or PPP 
added to 1.0 mL of cold extraction solution consisting of acetonitrile, isopropanol (IPA) 
and water (3:3:2, v/v/v)102. Samples were vortexed for 5 minutes at 4°C and centrifuged 
for 2 minutes at 14,000 relative centrifugal force (rcf). A total of 450μL of the supernatant 
was dried under a cold trap concentrator and then reconstituted with 450μL ACN:water 
(50:50 v/v) solution, centrifuged for 2 minutes at 14,000 rcf, and then subjected to drying 
under a cold trap. Derivatization occurred with the addition of 10μL of 40 mg/mL 
methoxyamine hydrochloride solution to the dried samples and quality controls, including 
N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) and fatty acid methyl esters 
(FAME). Samples were shaken at 30oC for 1.5 hours, then mixed with 91μL of MSTFA 
and FAME. After shaking at maximum speed at 37oC, for 30 minutes, the contents were 
transferred for metabolomic acquisition via gas chromatography mass spectrometry 
(GCMS)27.  
4) Lipidomic and Metabolomic Data Acquisition 
4a) LC-MS Lipidomic data acquisition 
Reverse phase, untargeted analysis was performed with a Sciex TripleTOF 6600 
coupled to an Agilent 1290 LC. Lipids were separated on an Acquity ultra-performance 
liquid chromatography (UPLC) CSH C18 column (100 × 2.1 mm; 1.7µm) (Waters, Milford, 
MA, USA) as previously reported by our group28. The column was maintained at a 
temperature of 65 °C with a constant flow-rate of 0.6mL/min. The mobile phases were 
Mobile Phase A at 60:40 (v/v) ACN:water with 10 mM ammonium acetate, and Mobile 
Phase B at 90:10 (v/v) IPA:ACN with 10 mM ammonium acetate. Lipid separation was 
conducted following a stepwise gradient program as follows: 0-2 minutes (Mobile Phase 
B: 15-30%), 2-2.5 minutes (Mobile Phase B: 48%), 2.5-11 minutes (Mobile Phase B: 
82%), 11-11.5 minutes (Mobile Phase B: 99%), 11.5-12 minutes (Mobile Phase B: 99%), 
12-12.1 minutes (Mobile Phase B: 15%), 12-14 minutes (Mobile Phase B: 15%). Negative 
and positive electrospray ionization (ESI) modes were applied with nitrogen serving as 
the desolvation gas and the collision gas. The MS instrument parameters were as follows: 
curtain gas: 35; collision-induced dissociation (CAD): high; ion spray voltage: 4500V; 
source temperature: 350°C; gas 1: 60; gas 2: 60; declustering potential: ±80V, and a 
collision energy of ±10103. 
4b) LC-MS Metabolomic data acquisition 
Detection of water-soluble PPP and FF metabolites underwent separation via 
normal phase LC on a Sciex TripleTOF 6600 coupled to Agilent 1290 LC103. Metabolites 
were separated by an Acquity UPLC BEH Amide (130Å, 1.7 μm, 2.1 mm X 150 mm) 
column (Waters, Milford, MA, USA). Column temperature was maintained at 45°C at a 
constant flow-rate of 0.4 mL/min. Two mobile phases were utilized, consisting of Mobile 
Phase A, which was LC-MS grade water with 10 mM of ammonium formate and 0.125% 
formic acid, and Mobile Phase B at 90:10 (v/v) ACN:water with 10 mM of ammonium 
formate and 0.125% formic acid. Analytes were separated using a stepwise gradient 
program as follows: 0–2 minutes (Mobile Phase B: 100%), 2–7.7 minutes (Mobile Phase 
B: 70%), 7.7–9.5 minutes (Mobile Phase B: 40%), 9.5–10.25 minutes (Mobile Phase B: 
30%), 10.25–12.75 minutes (Mobile Phase B: 100%), 12.75–16.75 minutes (Mobile 
Phase B: 100%). Injection volumes were 1μL and 3μL for the positive and negative 
modes, respectively. Positive and negative ESI modes utilized nitrogen serving as the 
desolvation gas and the collision gas, and the MS instrument parameters were: curtain 
gas: 35; CAD: high; ion spray voltage: 4500V; source temperature: 300°C; gas 1: 60; gas 
2: 60; declustering potential: ± 80V, and collision energies ± 10103.  
4c)  GC-MS Metabolomic data acquisition 
Metabolites were acquired on a Leco Pegasus IV time of flight mass spectrometer, 
coupled with an Agilent 6890 GC that was equipped with a Gerstel automatic liner 
exchange system (ALEX) that had a multipurpose sample (MPS2) dual rail, and a Gerstel 
CIS cold injection system (Gerstel, Muehlheim, Germany)102. The transfer line was 
maintained at 280°C, and separation was achieved on a 30 m long, 0.25 mm i.d. Rtx-5Sil 
MS column (0.25 μm; 95% dimethyl 5% diphenyl polysiloxane film) with a built-in, 
integrated guard column (10m; Restek, Bellefonte PA) with a constant flow (1 mL/min) of 
helium (99.999%; Airgas, Radnor, PA, U.S.A.) as the carrier gas. The oven temperature 
was held constant at 50°C for 1 minute, and then ramped at 20°C/min to 330°C, which 
was held constant for 5 minutes. The GC temperature program was set as follows: 50°C 
to 275°C final temperature at a rate of 12°C/s and held for 3 minutes. The injection volume 
was 1 μL in splitless mode at 250°C. Electron impact ionization at 70  was employed with 
an ion source temperature of 250°C. The scan mass ranged from 85-to-500 Da with an 
acquisition rate of 17 spectra/second102.  
5) Statistical Analysis 
 Baseline characteristics and demographic parameters were assessed for any 
significant (p<0.05) differences that could confound our findings between women with 
obesity and healthy-weight women undergoing IVF. Lipidomic and metabolomic data 
were acquired as ratios of mass-to-charge, and were normalized by mTIC to enable the 
merger of these two datasets, obtained from different instruments and techniques102. 
Metabolic data were filtered to exclude any detected exogenous metabolites identified as 
products of gut microbiota so that we obtained only endogenous metabolites, relevant to 
the physiological response of the patient undergoing IVF. Winsorization of outliers 
occurred for any value outside of 1.5 times the interquartile range104, and missing values 
for EHR data were imputed by the median of the variable. Any missing values for the 
outcome measures, 6-week pregnancy (a binary of “yes” or “no”) and 2PN (nominal) were 
excluded. Then the data were log-transformed and pareto-scaled to correct for technical 
variation and other factors not attributable to induced biological variation105. 
Phospholipids were identified by their head group, parent-fragment pair, and by their sum 
fatty acid composition. 
An overview of the statistical analytical workflow is presented within Figure 1, and 
this analysis was performed separately for FF and PPP analytes. Four domain models 
were used to ascertain the most important predictors belonging to lipids, metabolites, and 
EHR data for our chosen outcomes. These models consisted of either strictly metabolites, 
EHR data, or lipids, with two models containing either with glycerophospholipids (and 
lysophospholipids) or excluding glycerophospholipids. We performed stepwise multiple 
linear regression analysis (MLRA) with forward selection of candidate predictors among 
EHR, lipids, and metabolites that best fit BMI and 2PN. For our binary outcome of 6-
weeks pregnancy, we conducted a stepwise, regularized linear discriminant analysis 
(rLDA) to discriminate between pregnant and non-pregnant women. Lastly, predictors 
from lipids, metabolite, and EHR models were combined into a multi-component model 
for the final discriminant analysis model. To control for confounders, univariate models 
assessed whether selected predictors were also associated with confounders, and if so, 
the final multivariable model was fit to identify discriminatory lipids and metabolites after 
adjusting for potential confounders. The statistical analysis described herein was 
performed with JMP14Pro, MetaboAnalyst 4.0, and with R-scripts written by us. 
 
Figure 1: Statistical analysis workflow.  
 
Results 
Current clinical evidence for IVF success or failure have been methodologically 
limited, and this is problematic as lipids and cholesterol species in particular display high 
levels of compositional and functional heterogeneity. For example, cholesteryl esters, the 
single most abundant lipid class in human plasma and preferred form of cholesterol in 
lipoprotein particles, consist of several hundreds of molecular species106. We sought a 
qualitative approach to best characterize specific lipid species and metabolites that could 
sufficiently determine embryo quality and predict pregnancy outcomes in women with 
obesity following IVF.  
Characteristics of the study cohort and adjustments by Fasting Insulin 
 At the enrollment of this study, patients in either weight group had similar 
distributions of age, maximal serum estradiol, highest dosage of FSH used, total 
cumulative FSH used, and dietary scores (Table 1). T-tests at baseline determined no 
statistically significant (p>0.05) difference between demographic parameters for the 
treatment groups, except with BMI (p<0.0001), fasting insulin concentrations (p = 0.001), 
and the homeostatic model assessment for insulin resistance (HOMA-IR, p = 0.003). 
Because of this difference in insulin resistance, features selected for the final models of 
2PN, BMI, and 6-weeks pregnancy outcomes were adjusted by fasting insulin 
concentrations. Interestingly, when considering only weight class, both obese and 
healthy-weight groups had similar 6-weeks pregnancy (p = 0.229) and 2PN (p = 0.208) 
outcomes following IVF (Table 1). 
Table 1. Demographic and Baseline characteristics shows the similarities between normal 
weight women (not obese) and obese women  
 Normal (n=10) Obese (n=16)  p-value 
Female age, mean (SD) 33.30(5.1) 33.99(3.2) 0.712  
BMI 21.71(1.7) 34.42(9.7) <0.0001 
Fasting glucose  84.7(4.42) 87.12(7.11) 0.29 
Fasting insulin 4.63(2.06) 11.01(1.53) 0.001 
HOMA-IR 0.97(0.466) 2.31(1.47) 0.003 
Mediterranean diet score 25.1(7.35) 22.06(1.67) 0.303 
Total score black food fat 
screener 
14.4(7.39) 17(5.93) 0.361 
Total score block 
questionnaire fruit 
vegetable 
13(3.43) 11.06(4.73) 0.240 
Average setting 335.57(131.24) 311.51(169.62) 0.689 







Highest dosage of FSH 
used 
397.5(50.62) 389.06(73.58) 0.732 
Total cumulative FSH 
used 
4327.5(1392.86) 4397.65(1375.86) 0.901 
Maximal serum estradiol 1312.78(739.94) 1511.425(952.54) 0.557 
 6 weeks pregnancy 0.5(0.527) 0.25(0.447) 0.229 
2PN 17.1(10.80) 11.68(2.34) 0.208 
Note, 2PN=2 polar bodies, SD= Standard Deviation, BMI= Body Mass Index, HOMA ISI= Homeostatic model 
assessment Insulin Sensitivity Index. Data presented as mean (SD).  
Domain Independent and multicomponent MLRA models predict 2PN values with 
lipids and organic compounds, differing across PPP and FF matrices 
The EHR model for predicting 2PN retrieved female age in years, fasting glucose, 
fasting insulin, Mediterranean diet score, the total score from the block food questionnaire 
fat screener (23 high), the total score from the block food questionnaire fruit and vegetable 
screener (11 low), average sitting time as total minutes per day (test statistic = 0.665, 
Prob > |t| = 0.0221), and total cumulative FSH used (test statistic = -1.44, Prob > |t| = 
0.0015) as covariates, while only the average sitting time (total of minutes per day) was 
negatively associated with an increase in 2PN values (R adjusted = 0.769, RMSE = 
0.144). From the EHR data used to construct this model, only average sitting time and 
total cumulative FSH used were the clinical parameters that were significant after two-
way hypothesis testing.  Yet in constructing the MLRA model, predictors are covaried with 
another, thus those that were non-significant following a two-way hypothesis test were 
kept within this clinical parameter model and all remaining MLRA models. 
 
- Metabolites acquired from PPP allowed for the best fit model across other domain 
models for 2PN values 
Without exclusion of PPP lipids belonging to the glycerophospholipid (PL) family, we 
observed the following to best predict increasing 2PN values: PL that decreased in 
circulating with increasing 2PN numbers were lysophosphatidylcholine (LPC) 22:6 (test 
statistic = -1.01, Prob > |t| = 0.0231), phosphatidylcholine (PC) 16:1/22:6, and  
phosphatidylethanolamine-plasmalogen (PE-P) 16:0/22:6 (test statistic = -0.899, Prob > 
|t| = 0.0004). Phosphatidylethanolamine (PE) 18:0/20:3, lysophosphatidylethanolamine 
(LPE) 18:1 (test statistic = 0.928, Prob > |t| = 0.0005), PC 14:0/16:1 (test statistic = 0.4698, 
Prob > |t| = 0.0060), and PE-P 16:0/20:5 (test statistic = 0.483, Prob > |t| = 0.0013) were 
those PL that were either positively associated or correlated with 2PN (R adjusted = 
0.730, RMSE = 0.329). 
Exclusion of PL and inclusion of other lipid species from our PPP model derived a 
model with poorer fit for 2PN (R adjusted = 0.666, RMSE = 0.365). Nonetheless, we found 
the following nonesterified fatty acids (FFA) and cholesteryl esters (CE) to be associated 
or correlated with 2PN: those that increased with 2PN values included CE 14:0, CE 20:5 
(test statistic = 0.931, Prob > |t| = 0.0236), FFA 19:1 (test statistic = 1.01, Prob > |t| = 
0.0288), and myristic acid. Inversely, those that decreased corresponding a rise in 2PN 
values were CE 16:0, CE 22:6 (test statistic = -1.555, Prob > |t| = 0.0007), FFA 14:1, FFA 
18:2, FFA 20:5, and lauric acid (test statistic = -0.771, Prob > |t| = 0.0137). 
 Comparatively, the metabolic model performed better against both lipid domain 
models and the final model (R adjusted = 0.749, RMSE = 0.317), as depicted in Figure 
2, and included the following small molecules: 2-ketoisovaleric acid (test statistic = -0.971, 
Prob > |t| = 0.0001), 3-aminoisobutyric acid (test statistic = -0.611, Prob > |t| = 0.0004), 
beta alanine (test statistic = -0.638, Prob > |t| = 0.0007), glutamic acid (test statistic = -
0.887, Prob > |t| = 0.0002), and serine (test statistic = -0.897, Prob > |t| = 0.0033) were 
negatively correlated with 2PN. However, those metabolites that were positively 
correlated with 2PN values involved aspartic acid (test statistic = 0.500, Prob > |t| = 
0.0236), ornithine (test statistic = 0.683, Prob > |t| = 0.0225), and phosphate (test statistic 
= 0.852, Prob > |t| = 0.0030). 
 
Figure2: Metabolites model for 2PN acquired from PPP sample. 
When combining all data domains, the final model for PPP to predict 2PN values was 
constructed: positively correlated analytes included LPE 20:4 (test statistic = 0.765, Prob 
> |t| = 0.0023), PC 14:0/16:1 (test statistic = 0.255, Prob > |t| = 0.0329), and phosphate 
(test statistic = 1.03, Prob > |t| = 0.0003). Negatively correlated predictors were LPC 22:6 
(test statistic = -0.652, Prob > |t| = 0.0057), CE 16:0 (test statistic = -0.595, Prob > |t| = 
0.0056), and FA 20:5 (test statistic = -0.289, Prob > |t| = 0.0212). Although better fit than 
the lipid models (R adjusted = 0.727, RMSE = 0.331), the combined model performed 
worse than the PPP metabolites model for 2PN. 
 
- Including Glycerophospholipids produced the best fit FF model for predicting 2PN 
values against other Lipid, Metabolic, and Combined domain models 
Inclusion of PL from FF generated a model that included two acylcarnitine species as 
well various PLs. Acylcarnitine C16:0 (test statistic = 0.417, Prob > |t| = 0.0033), 
containing palmitic acid, was positively correlated with 2PN values, yet acylcarnitine 
C18:1 (test statistic = -0.542, Prob > |t| = 0.0358), or an L-carnitine esterified with oleic 
acid, was negatively correlated. Retained PL from FF that decreased with 2PN values 
were LPC 16:1 (test statistic = -0.853, Prob > |t| = 0.0047), lysophosphatidylinositol (LPI) 
18:2 (test statistic = -1.00, Prob > |t| = 0.0023), and PC-Plasmalogen (PC-P) 18:0/22:6 
(test statistic = -0.799, Prob > |t| = 0.0013). Those PL that were positively correlated with 
2PN numbers were LPC 22:4 (test statistic = 0.603, Prob > |t| = 0.0028), LPE 20:4 (test 
statistic = 0.927, Prob > |t| = 0.0042), and LPI 18:1 (test statistic = 1.16, Prob > |t| = 
0.0048).  Of the FF models, this model performed the best for predicting 2PN values (R 
adjusted = 0.755, RMSE = 0.312), the results of which can be viewed in Figure 3.  
 
Figure 3: PL model for 2PN acquired from FF sample. 
From our FF lipid model (R adjusted = 0.726, RMSE = 0.331) excluding PL, lipids that 
positively associated or correlated with 2PN involved CE 16:1, CE 18:1 (test statistic = 
1.26, Prob > |t| = 0.0009), and arachidic acid. Among the negatively associated or 
correlated lipids, when excluding PL, included CE 18:3, CE 22:6 (test statistic = -0.914, 
Prob > |t| = 0.0003), FA 14:0 (test statistic = -0.439, Prob > |t| = 0.0410), FA 16:0 (test 
statistic = -0.585, Prob > |t| = 0.0410), FA 22:3 (test statistic = -0.894, Prob > |t| = 0.0003). 
Metabolites acquired from FF were all negatively correlated with 2PN values, with the 
exception of 1-monoolein, which bore a positive association with increasing 2PN. 
Nonetheless, the metabolites from our model included 2-aminobutyric acid (test statistic 
= -0.646, Prob > |t| = 0.0021), alanine (test statistic = -1.09, Prob > |t| = <0.0003), hexose 
(test statistic = -0.591, Prob > |t| = <0.0010), phenylalanine (test statistic = -0.908, Prob 
> |t| = 0.0108), and phenylethylamine (test statistic = -0.975, Prob > |t| = 0.0002). Despite 
the metabolites model performing better than the FF lipid model excluding PL (R adjusted 
= 0.7299, RMSE = 0.329), metabolites alone failed to outperform the FF lipid model 
including PL.  
A final model with all 4 data domains gave a model without any EHR parameters (R-
squared adjusted = 0.748, RMSE = 0.317). Lipids and metabolites selected were 
negatively correlated or associated with 2PN values except arachidonic acid containing 
LPE 20:4 (test statistic = 0.854, Prob > |t| = 0.0040). Remaining molecules were PC-P 
18:0/22:6 (test statistic = -0.622, RMSE = 0.0115), 2-aminobutyric acid, alanine (test 
statistic = -0.771, RMSE = 0.0062), phenylethylamine, and FA 22:3 (test statistic = -0.429, 
RMSE = 0.0438). 
 
Regularized Linear Discriminant analysis (rLDA) of 6-weeks of pregnancy  
Pregnancy was discretized as a binary, categorical outcome, or as either “yes” (1) 
or “no” (0), 6-weeks after IVF. Ergo, the objective of these stepwise, regularized linear 
discriminant analytical (rLDA) models was to classify patients along this binary107. EHR 
data alone surprisingly gave the highest rate of misclassification (19.23%) and the poorest 
entropy R-squared, a measure of classification quality or goodness of separation, across 
all of the component models (Entropy R-squared = 0.356). EHR parameters included in 
this model were female age, fasting glucose, Mediterranean diet score, total score block 
food fat screener (23 high), total score block food fruit and vegetable screener (11 low), 
average sitting time (total of minutes per day), total cumulative FSH used, and maximal 
serum estradiol value. A 95% confidence level ellipse was plotted for each canonical 
variables mean, pregnant or non-pregnant, as well as an ellipse denoting a 50% contour 
for each group, depicting a region that contains approximately 50% of the observations. 
The set of rays in the biplot represents the covariates, whose coefficients in the linear 
combination were canonical weights. Thus, the larger a covariate’s canonical weight, the 
greater its association with the canonical variable. The length and direction of each ray in 
the biplot indicates the degree of association of the corresponding covariate with the 
canonical variable, 6-weeks pregnant or failed pregnancy (Figure 4). 
 
Figure 4: rLDA of 6-weeks of pregnancy and EHR. 
- High goodness of separation without misclassification for 6-weeks pregnancy 
outcomes was achieved with the Metabolite model obtained from Platelet Poor 
Plasma 
In classifying patients into their pregnancy status following IVF, lipids obtained from 
PPP that did not include the glycerophospholipid (GL) class resulted in one false positive 
(misclassification = 3.85%, Entropy R-squared = 0.809). Five lipid species were 
associated with pregnancy failure, those involving CE 17:1 (standardized scoring 
coefficient = -1.64), CE 22:5 (standardized scoring coefficient = -3.67), FA 20:4 
(standardized scoring coefficient = -3.08), capric acid (standardized scoring coefficient = 
-1.47), and lauric acid (standardized scoring coefficient = -1.72). Successful pregnancies 
were associated with higher concentrations of CE 18:3 (standardized scoring coefficient 
= 3.69), CE 20:4 (standardized scoring coefficient = 1.99), CE 20:5 (standardized scoring 
coefficient = 1.49), FA 20:2 (standardized scoring coefficient = 2.51), arachidic acid 
(standardized scoring coefficient = 2.26), and myristic acid (standardized scoring 
coefficient = 2.17). 
No change was observed in the percent misclassification (3.85%), nor the number of 
false positives, when GL species were included as covariates of the lipid model (Entropy 
R-squared = 0.813). Of note was that circulating total cholesterol (standardized scoring 
coefficient = 0.350) was positively associated with 6-weeks pregnancy following IVF. 
Other positively associated covariates included LPE 20:4 (standardized scoring 
coefficient = 2.60), PC 16:1/18:2 (standardized scoring coefficient = 0.880), PC 17:0/20:3 
(standardized scoring coefficient = 1.28), and PI 16:0/18:1 (standardized scoring 
coefficient = 0.964). 
With regards to the metabolite model, none of the patients were misclassified into their 
pregnancy groups, and relatively high goodness of separation was attained (Entropy R-
squared = 0.939). Metabolites, with the exception of 2-ketoisovaleric acid (standardized 
scoring coefficient = -1.02), glucose-1-phosphate (standardized scoring coefficient = -
0.945), and ornithine (standardized scoring coefficient = -1.19), were positively 
associated with pregnancy and can be viewed in Figure 5. These metabolites were 2-
hydroxyglutaric acid (standardized scoring coefficient = 1.71), serine (standardized 
scoring coefficient = 1.15), threonine (standardized scoring coefficient = 1.42), and uric 
acid (standardized scoring coefficient = 1.47). 
 
Figure 5: rLDA of 6-weeks of pregnancy and metabolites acquired from PPP. 
A final model was constructed without clinical parameters, containing only lipids and 
metabolites. Total cholesterol (standardized scoring coefficient = 1.30) was positively 
associated with pregnancy outcomes, as well as LPE 20:4 (standardized scoring 
coefficient = 1.21), uric acid (standardized scoring coefficient = 1.08), and arachidic acid 
(standardized scoring coefficient = 0.753). Negatively associated lipids and metabolites, 
or those that were higher with negative pregnancy outcomes, were LPC 20:4 
(standardized scoring coefficient = -1.77), 2-ketoisovaleric acid (standardized scoring 
coefficient = -0.818), and lauric acid (standardized scoring coefficient = -0.452). 
 
- Lipids excluding Glycerophospholipids obtained from Follicular Fluid resulted in No 
Misclassification and the Best Separation for 6-weeks pregnancy groups 
Classification of the 6-week pregnancy groups was achieved with 0% misclassification 
and high goodness of separation (Entropy R-squared = 0.977) when using a model of 
lipids, excluding from selection all GL species. Covariates that were weighted heavily 
towards pregnancy failure included CE 20:5 (standardized scoring coefficient = -0.959), 
capric acid (standardized scoring coefficient = -0.870), and stearic acid (standardized 
scoring coefficient = -1.08). Pregnancy success was associated with higher levels of CE 
18:3 (standardized scoring coefficient = 1.31), FA 18:3 (standardized scoring coefficient 
= 0.867), heptadecanoic acid (standardized scoring coefficient = 1.71), and palmitoleic 
acid (standardized scoring coefficient = 0.874). Comparatively, this lipid model performed 
the best against all other FF models for discrimination of the pregnancy classes (Figure 
6). 
 
Figure 6:  rLDA of 6-weeks of pregnancy and lipids without GL species acquired from FF 
sample. 
Coupling FF obtained lipid species with GL for a model of 6-week pregnancy was 
achieved with modest misclassification (7.69%) and admissible goodness of separation 
(Entropy R-squared = 0.750). Lysophospholipids and phospholipids predominated as the 
covariates of this model where IVF proved efficacious were more closely associated with 
LPC 14:0 (standardized scoring coefficient = 1.34), LPI 18:1 (standardized scoring 
coefficient = 0.830), LPI 20:4 (standardized scoring coefficient = 1.47), and PC 18:1/20:3 
(standardized scoring coefficient = 1.27). Patients who were classified as having not 
achieved pregnancy saw higher concentrations of LPC 20:2 (standardized scoring 
coefficient = -2.07), LPE 18:2 (standardized scoring coefficient = -2.07), and PC 16:0/20:4 
(standardized scoring coefficient = -1.06).  
Analogous to the 6-week pregnancy lipid model excluding glycerophospholipids, the 
metabolite model for FF had no misclassification (0%) and high goodness of separation 
(Entropy R-squared = 0.943). Only alpha-ketoglutarate (standardized scoring coefficient 
= -1.26) was associated with failed pregnancy. The remaining covariates of fumaric acid 
(standardized scoring coefficient = 0.793), hexose (standardized scoring coefficient = 
0.825), indole-3-propionic acid (standardized scoring coefficient = 0.566), and uric acid 
(standardized scoring coefficient = 1.35) were associated positively associated with 
pregnancy. 
 The final model of FF analytes and clinical parameters for 6-weeks pregnancy 
status resulted in one false negative (misclassification = 3.85%, Entropy R-squared = 
0.889). Despite including all variables across the data domains, only one lipid and 
metabolites were selected, of which were FA 18:3 (standardized scoring coefficient = 
0.616), fumaric acid (standardized scoring coefficient = 1.08), hexose (standardized 
scoring coefficient = 0.730), and uric acid (standardized scoring coefficient = 1.06) that 
were positively associated with pregnancy. A singular metabolite, alpha-ketoglutarate 
(standardized scoring coefficient = -1.29), was elevated in FF for those that did not 
achieve pregnancy. 
 
Domain Independent and domain-integrated MLRA models predict BMI values with 
phospholipids and fatty acid derivatives, varied across PPP and FF matrices  
Our EHR model for predicting BMI values retrieved fasting glucose, fasting insulin, 
and the total score from the block food questionnaire fat screener (23 high) as positively 
associated covariates, while only the average sitting time (total of minutes per day) was 
negatively associated (R adjusted = 0.769, RMSE = 0.144). Fasting insulin (test statistic 
= 0.473, Prob > |t| = <0.0001) and total score block food fat screener (23 high; test statistic 
= 0.167, Prob > |t| = 0.0054) were clinical parameters that were significant after two-way 
hypothesis testing.  As mentioned prior, in constructing the MLRA model, predictors are 
covaried with another, thus those that were non-significant following the two-way 
hypothesis test were kept within this clinical parameter model. 
 
- A multicomponent domain model for PPP outperformed data-domain independent 
Lipid, Metabolic, and EHR domain models for BMI 
With regards to our PPP PL model, LPC 18:1 (test statistic = -0.261, Prob > |t| = 
0.0133), LPC-P 16:0 (test statistic = -0.233, Prob > |t| = 0.0021), PC 16:1/22:6 (test 
statistic = -0.243, Prob > |t| = 0.0002), and PI 18:0/20:4 (test statistic = -0.268, Prob > |t| 
= 0.0422) were negatively correlated with an increase in BMI values, while, interestingly, 
recovered LPC 22:6 (test statistic = 0.305, Prob > |t| = 0.0127) and PC 16:0/22:4 (test 
statistic = 0.185, Prob > |t| = 0.0027) were positively correlated predictors of BMI values 
(R adjusted = 0.786, RMSE = 0.138).  
From our lipid model excluding PL, lipids that were positively correlated with BMI 
were CE 18:0 (test statistic = 0.467, Prob > |t| = 0.0014), CE 20:3 (test statistic = 0.364, 
Prob > |t| = 0.0015), FA 17:1 (test statistic = 0.691, Prob > |t| = 0.0005), 
and heptadecanoic acid (test statistic = 0.413, Prob > |t| = 0.0005), while CE 22:4 (test 
statistic = -0.869, Prob > |t| = <0.0001), FA 14:1 (test statistic = -0.904, Prob > |t| = 
<0.0001) were negatively correlated (R adjusted = 0.726, RMSE = 0.156). 
The metabolic model using PPP metabolites demonstrated that 2-hydroxyglutaric 
acid (test statistic = -0.203, Prob > |t| = 0.0189), malic acid (test statistic = -0.225, Prob > 
|t| = 0.0349), serine (test statistic = -0.620, Prob > |t| = <0.0001), and alanine (test statistic 
= -0.315, Prob > |t| = 0.0144) were negatively correlated with BMI, yet tyrosine (test 
statistic = 0.276, Prob > |t| = 0.0157), glucose-1-phosphate (test statistic = 0.307, Prob > 
|t| = 0.0015) were positively correlated (R adjusted = 0.739, RMSE = 0.152). 
Inclusion of predictors from all domain models (EHR, PL exclusive, excluding PL, 
and metabolites) presented the final model with negatively correlated LPC 18:1 (test 
statistic = -0.210, Prob > |t| = 0.0244), PC 16:1/22:6 (test statistic = -0.090, Prob > |t| = 
0.0594), and malic acid (test statistic = -0.207, Prob > |t| = 0.0239) where only PC 
16:1/22:6 was not significant following a two-way t-test. Fasting insulin (test statistic = 
0.269, Prob > |t| = 0.0018) and PC 16:0/22:4 (test statistic = 0.163, Prob > |t| = 0.0044) 
were positively correlated with BMI values (R-square adjusted = 0.819, RMSE = 0.127). 
A visualization of this final model for BMI from EHR data and PPP small molecules can 
be found in Figure 7. 
 
Figure 7: Final model for BMI from EHR data and PPP small molecules. 
- Combined data domains for FF  enabled the best prediction of BMI values against the 
other Lipid, Metabolic, and EHR domain models 
As determined from FF, the PL model selected fewer lipid species such as LPC 
18:2 (test statistic = -0.390, Prob > |t| = 0.0061), and LPC-(11Z-octadeceneyl) (LPC-O) 
18:1 (test statistic = -0.466, Prob > |t| = 0.0006) which were negatively correlated with 
BMI values. Those PL that were positively correlated with BMI included LPC 20:2 (test 
statistic = 0.385, Prob > |t| = 0.0280), PC 20:3/20:4 (test statistic = 0.193, Prob > |t| = 
0.0003) and PE-P 16:0/22:6 (test statistic = 0.478, Prob > |t| = <0.0001). With fewer lipids, 
the FF PL model achieved a greater fit with a lower RMSE (R adjusted = 0.797, RMSE = 
0.134).  
From our FF lipid model excluding PL, lipids that positively correlated with BMI 
involved CE 20:3 (test statistic = 0.855, Prob > |t| = <0.0001), FA 19:0 (test statistic = 
0.259, Prob > |t| = 0.0028), and FA 22:2 (test statistic = 0.356, Prob > |t| = 0.0239) while 
CE 16:0 (test statistic = -0.389, Prob > |t| = 0.0236), CE 18:3 (test statistic = -0.548, Prob 
> |t| = 0.0004), FA 18:1 (test statistic = -0.648, Prob > |t| = 0.0009) were lipids negatively 
correlated with BMI (R adjusted = 0.706, RMSE = 0.162). 
Few FF metabolites were required to predict BMI values with good fit, those being 
aspartic acid (test statistic = 0.413, Prob > |t| = 0.0003) and tyrosine (test statistic = 0.583, 
Prob > |t| = <0.0001) that were positively correlated, and histidine (test statistic = -0.377, 
Prob > |t| = 0.0285) and indole-3-propionic acid (test statistic = -0.241, Prob > |t| = 0.0008) 
negatively correlated with BMI (R adjusted = 0.754, RMSE = 0.148). 
A combination of all 4 components yielded a final model with PE-P 16:0/22:6 (test 
statistic = 0.206, Prob > |t| = 0.0040), aspartic acid (test statistic = 0.207, Prob > |t| = 
0.0141), and fasting insulin (test statistic = 0.269, Prob > |t| = <0.0001) as positively 
correlated variables with BMI values, whereas indole-3-propionic acid (test statistic = -
0.225, Prob > |t| = <0.0001) was negatively correlated with BMI (R-squared adjusted = 
0.856, RMSE = 0.113), the results of which can be viewed in Figure 8. 
 
Figure 8: Final model for BMI from EHR data and FF small molecules. 
Discussion 
This study was able to determine the metabolite and lipid profiles that were specific 
to changes in body weight, associated with pregnancy outcomes, and correlated to 
embryo quality following in vitro fertilization (IVF). By measuring two distinct matrices of 
26 women, platelet poor plasma (PPP) and follicular fluid (FF), we delineated what matrix 
interactions were present on the composition of these significant metabolites and lipids 
and found inter-matrix fluctuations in the levels of these analytes that corresponded with 
our chosen pregnancy outcomes. Several studies have explored the utility of 
metabolomics to assess pregnancy outcomes in women of varying weight class 
subsequent IVF, yet were restrained in their findings by the level of specificity in their 
analyses or by not considering matrix effects94–97.  
Maternal central carbon metabolism undergoes substantial alterations early in 
gestation. One such example includes 2-hydroxyglutaric acid (2-HG), a derivative of 
Krebs cycle intermediate 2-oxoglutarate that, when obtained from PPP, was positively 
associated with pregnancy. Respiratory alkalosis is a common acid-base disorder that is 
observed in pregnancies, and the L-enantiomer of 2-HG accumulates in the context of a 
hypoxic ventilatory response to alleviate reductive stress108–112. With regards to 
pregnancy, the metabolic pathway of L-2-HG in humans is poorly characterized and 
requires further study. Carbohydrates and lipid metabolites have also served as putative 
markers of embryo quality97,113,114. Glucose-1-phosphate (G-1-P) obtained from PPP 
(Figure 5), at high concentrations, was negatively associated with pregnancy; notably, 
pregnancy alters glucose-6-phosphate dehydrogenase activity resulting in enzymatic 
deficiency115. Furthermore, plasma concentrations of glycogen phosphorylase, which 
catalyzes the rate-limiting step of glycogen to G-1-P, are elevated in pregnant women 
experiencing preterm preeclampsia116. We found that in PPP, the higher the 
concentration of phosphate, the greater 2PN values. Phosphate serves as an intracellular 
buffer and regulates the death of hypertrophic cells via caspase-9-mediated pathways117. 
Mechanistic studies on oocyte progression to the blastocyst stage however have 
demonstrated that media devoid of glucose and phosphate, but enriched in glutamine, 
improves the development of embryos118,119, complicating the interaction between 
phosphate and oocyte maturation.  
Amino acid metabolism is also altered throughout the course of pregnancy; relative 
to the first trimester, 2-ketoisovaleric acid, a keto-acid (BCKA) intermediate within 
branched-chain amino acid catabolism (BCAA), has been shown to decrease in 
plasma112,120. Elevated 2-ketoisovaleric acid (KV) is indicative of impaired BCAA, where 
an accumulation of toxic BCKA can promote the development of type 2 diabetes 
mellitus120. Our results confirm the deleterious effects of accumulated BCKA like KV, 
when obtained from PPP, as higher KV was correlated with lower 2PN values and was 
negatively associated with clinical pregnancies. From our study, plasma concentrations 
of 3-aminoisobutyric acid (BAIBA) and glutamic acid decreased with 2PN values. 
Degradation of BAIBA, an endogenous protective myokine, regulates adipose tissue 
browning and improves insulin sensitivity121. A reduction in the turnover rate, or a higher 
concentration, of amino acids like glutamic acid track with meiotic phase progression. An 
increase in glutamic acid corresponds with oocyte degradation122. Pregnancy is a period 
of extreme physiological demand for protein synthesis. The anionic form of glutamic acid, 
glutamate, plays a vital role in protein synthesis and persists at low concentrations 
throughout gestation so that proteins may be retained to meet the metabolic demand; 
hence, elevated glutamic acid may indicate a breakdown in protein synthesis123. Obtained 
from PPP, ornithine was elevated in response to higher 2PN values (Figure 2), however 
curiously higher ornithine concentrations corresponded with unsuccessful pregnancy 
following IVF. Ornithine can act as a substrate for putrescine synthesis, a conjugate base 
that positively influences oocyte maturation; however, elevation of ornithine may also 
correspond with an inborn error in the urea cycle124,125. Future studies that parse out the 
exact role plasma ornithine has towards pregnancy outcomes.   
When eliciting the effect of fatty acids (FA), it is of great import to determine where 
particular FAs are sequestered within the lipidome. Our analysis revealed free fatty acid 
and glycerophospholipid species consisting of capric acid (FA 10:0), palmitic acid (FA 
16:0), palmitoleic acid (FA 16:1), heptadecanoic acid (FA 17:0), stearic acid (FA 18:0), 
oleic acid (FA 18:1), linoleic acid (FA 18:2), ɑ-linoleic acid (FA 18:3), arachidonic acid (FA 
20:4), docosatetraenoic acid (FA 22:4), and docosahexaenoic acid (FA 22:6) to elicit 
differential effects on embryo quality, body mass composition, and clinical pregnancy 
outcomes, dependent upon matrix. Accumulation of nonesterified FA 10:0 and FA 18:0 in 
FF was found to be negatively associated with 6-weeks clinical pregnancy, while greater 
concentrations of FA 17:0 and FA 18:3 were positively associated with achieving clinical 
pregnancy post IVF. Capric acid (FA 10:0) regulates inflammation by functioning as a 
modulating ligand for peroxisome proliferator-activated receptors, and by interfering with 
nuclear factor kappa beta activation126,127. Stearic acid (FA 18:0) along with palmitic acid 
(FA 16:0), which are the predominant saturated free fatty acids in FF128, activate 
inflammatory signaling pathways and can induce endoplasmic reticulum stress129,130. 
Previous studies found that embryos which released greater concentrations of FA 10:0 
and FA 18:0 into the microenvironment emulsion saw a greater reduction in birth131. 
Conversely, FA 18:3, an essential ⍵-3 polyunsaturated FA, is evinced to increase the 
number of mature oocytes in a dose-dependent fashion132. Additionally, high 
concentrations of cholesteryl esters (CE) bearing FA 18:3 (CE 18:3) were positively 
associated with pregnancy, while CE 20:5 higher concentrations in FF were negatively 
associated with pregnancy. Cholesteryl esters can accumulate in steroidogenic cells as 
well as in pools of lipid droplets; their main functions are to store and transport cholesterol 
as well as PUFA133. These PUFA are then integrated into steroidogenesis, and can serve 
as precursors to prostanoids and lipoxygenase products as well as signaling 
molecules134. 
The number of two polar bodies (2PN) increased with higher concentrations of LPI 
18:1, LPE 20:4, LPC 22:4 in FF, whereas LPC 16:1 and LPI 18:2 were negatively 
correlated with 2PN. Interestingly, absolute plasma concentrations of LPI 18:2 among 
other lysophospholipids (lysoPL) are significantly reduced with gestational diabetes 
mellitus (GDM), possibly due to an altered glucose metabolism; additionally, the ratio of 
saturated lysoPL - to - unsaturated lysoPL is higher during pregnancy with GDM, 
indicating that lysoPL acyl moieties may determine the effect of lysoPL species in lipid 
metabolic pathways135. Platelet poor plasma LPC 18:1, a purported inhibitor of reactive 
oxygen species synthesis and neutrophil effector responses, was found here to negatively 
correlate with BMI values136. Species such as LPC 20:4 and LPC 22:4 can potentiate anti-
inflammatory effects, neutralizing LPCs that have been shown to transduce pro-
inflammatory signals such as LPC 16:0, and these very species are known to be altered 
significantly in the serum of obese women137,138. Lysophospholipids therefore may serve 
as markers of oxidative stress, lipotoxicity, and other inflammatory factors that regulate 
embryo quality and body composition109,138,139. Yet the physiological role of 
lysophospholipids, especially by their native matrix, are nascently understood despite 
their apparent involvement in numerous inflammatory, proliferative, and cytoskeletal 
responses as signaling molecules138.  
 Stereoisomeric and structural, or “positional”, isomeric lipids can have markedly 
different biological ramifications for overall health and pregnancy outcomes. The position 
of a fatty acyl moiety affects its distribution in phospholipid species. Phosphatidylcholines 
(PC) such as PC 16:0/22:4 acquired from PPP, and PC 16:0/22:6 obtained from FF, were 
positively correlated with rising BMI values, while PC 16:1/22:6 was negatively correlated 
with BMI. Interestingly, PCs containing FA 22:6, an ⍵-3 polyunsaturated fatty acid that 
serves as a precursor for several pro-resolving lipid mediators140, varied here in its 
association with BMI dependent upon other fatty acyl chains in the sn1 position. While FA 
22:6 has also been linked to positively influence biochemical processes in fetal 
development141,142, these data exemplify the importance of metabolomic analyses to 
characterize the lipidome with a greater level of specificity that can capture the 
physicochemical properties of lipids.  
Palmitic acid is a saturated FA that at high concentrations induces a 
proinflammatory response, as determined by cytokine and adipokine profiling; 
furthermore, elevated nonesterified palmitate correlates with insulin resistance in 
pregnant women129 and at higher plasma concentrations is associated with a reduction in 
the number of births131. Reesterification of LPC to PC, and de novo synthesis of PC 
species such as PC 16:0/22:4, have been found to be amplified by the metabolic 
dysregulations typical of an obese state143. The inverse is true for palmitoleic acid (FA 
16:1) bearing PCs; additionally, we found nonesterified FA 16:1, when obtained from FF, 
at higher concentrations to be positively associated with clinical pregnancy, 6 weeks 
subsequent IVF. Palmitoleic acid is a lipokine that exhibits insulin-sensitizing and anti-
inflammatory properties. During maternal obesity, it has been reported that the synthesis 
of free form palmitoleic acid, and storage lipids bearing FA 16:1, is downregulated141. Two 
plasmalogens obtained from FF also correlated with pregnancy outcomes, with an 
ethanolamine plasmalogen (PE-P 16:0/22:6) positively correlating with BMI, and a choline 
plasmalogen (PC-P 18:0/22:6) negatively correlating with 2PN values. Concentrations of 
these lipid species tend to fluctuate with the physiological processes such as aging and 
serve as putative biomarkers of ovarian reserve when assayed from FF144. Although the 
functions of plasmalogens are not fully understood, the literature suggests that these 
lipids act as reservoirs of PUFA, such as FA 22:6, to be further metabolized into second 
messenger molecules involved in regulating inflammation144,145. 
Acylcarnitine species esterified to palmitate for example (acylcarnitine FA 16:0), 
when obtained from FF, increases with 2PN values. It has previously been reported that 
IVF may result in excess carnitine consumption and greater depletion of long-chain 
acylcarnitine pools by oocytes146. Ergo, a positive correlation for acylcarnitine C16:0 and 
2PN values may suggest metabolic processes, such as a complete tricarboxylic acid 
cycle, that follow the course of pregnancy. Additionally, oleic acid (FA 18:1) bearing 
acylcarnitines, when obtained from FF, decreased with 2PN values. Oocyte competence 
can be negatively impacted by saturated free fatty acids like stearic acid and palmitic acid. 
When not sequestered to β-oxidation, free form oleic acid and palmitoleic acid can 
stimulate the distribution of saturated FA towards neutral storage lipids and β-oxidation, 
away from apoptotic, pro-inflammatory pathways141(p),147,148. 
Uric acid was positively associated with clinical pregnancy, when it was obtained 
from PPP. Early pregnancy serum uric acid levels tend to fall, related to the uricosuric 
effects from estrogen. Uric acid is also positively associated with insulin resistance, hence 
this finding elicits further study as to determine why uric acid was positively associated 
with pregnancy. In general, uric acid concentration decreases during the first three 
months of normal pregnancy due to increased glomerular filtration rate (GFR). However, 
a previous study showed that the concentration of uric acid in the plasm of women 
undergoing IVF decreased less than the women who had a normal pregnancy149. To our 
knowledge, there are limited studies that assess kidney function and GFR in IVF.  Another 
possible explanation for our finding of uric acid increasing with pregnancy is that IVF may 
increase the chance of induction of preeclampsia150.  Conceptions achieved by IVF 
resulted in a greater risk to develop preeclampsia (2.7 times)151,152.  
Indole-3-propionic acid (IPA), synthesized from tryptophan and a natural product 
derived from the gut microbiota, has been associated with insulin secretion and 
sensitivity, and negatively correlated with low-grade inflammation. This could be due to 
IPA being the most potent scavenger of the hydroxyl radicals, and elevated 
concentrations of IPA in plasma is associated with reduced risk for incident type 2 
diabetes (T2D); yet this protective effect may be diminished or negated in patients who 
already have T2D. Obesity has had a documented signature on the metabolomic profile 
of FF, decreases IPA in FF as we determined here with higher BMI values. These data 
suggest that IPA obtained from FF may model antioxidant status, or a reflect the gut 
metabolism interacting with follicular development153. IPA can also reduce the levels of 
various lipid peroxidation markers and DNA damage. In a previous study using rats 
model, IPA was shown to improve the serum insulin resistance index, glucose, and insulin 
levels. Obesity has been studied in animals and humans. It causes alteration of bacterial 
species in the gut microbiome compared to controls. Considering this, Ruebel et al. 
hypothesized that obesity changes the profiles of bacteria species, reducing IPA 
production. Alternatively, the systemic inflammation caused by obesity could cause 
intestinal inflammation, which would modulate the gut microbiome and lower IPA levels. 
Future research in germ-free models will be needed to confirm this hypothesis as well as 
determine the role of FF IPA in oocyte maturation and development153. 
Malic acid from PPP is exogenous, obtained from a diet of citric fruits, and was 
also found to be negatively associated with BMI values (figure 7). Dietary choices and 
cooking methods may explain the decline for the obese group. The natural sources of 
malic acid (p = 0.026) are typically vegetables, berries, cherries, and citrus fruits; more 
recently, it has been incorporated into popular fruit vinegar drinks for its antioxidant 
properties and taste, suggesting that higher malic acid in PPP could result in a patient 
with lower systemic oxidative stress6 (Figure 6). As the relation between obesity and 
oxidative stress is well characterized in previous research154,155, an in vitro study shows 
that the decrease in malic acid concentration is an oxidative stress biomarker besides 
vitamin C156.  
Beta-alanine is a nonessential amino acid that was negatively associated with 2PN 
values as obtained from PPP (figure 2). During pregnancy, the development of 
gluconeogenesis is attenuated due to decreased alanine flux. This process is triggered 
by the intrahepatic mechanism which lowers the deamination of alanine157. It has been 
hypothesized that the metabolic cooperation between oocytes and follicular cells leads to 
the uptake of amino acids. In addition, these findings indicate that the cells do not have 
the capability to increase the level of leucine in mice. A liquid chromatography-tandem 
Mass spectrometry study revealed that the presence of aromatic amino acids in the fluid 
of polycystic ovary syndrome (PCOS) patients is associated with an increase in body 
mass index. These changes involve elevation of amino acids including glutamic acid, 
phenylalanine, alanine, and arginine. The study supports the notion that the lack of these 
nutrients can affect the quality of oocyte eggs. A previous study showed that evaluation 
of the non-invasive amino acid profiling of bovine oocytes with high-performance LC might 
be utilized to evaluate oocyte development in bovine. The results showed a significant 
decrease in glutamine and increase in alanine in the medium of oocytes that failed in the 
cleavage process after 3 days postfertilization122. 
Aspartic acid is interestingly correlated with higher BMI values as well as a greater 
number of 2PN. A previous study showed that increased aspartic acid in PCOS women 
is related to increased chance of getting pregnant158. In addition, D’Aniello et al. 
demonstrate a positive relation between aspartic acid elevation and egg quality in obese 
women undergoing IFV159. Furthermore, d-aspartic acid improves the synthesis of some 
hormones such as LH and testosterone160. The LH hormone released from the anterior 
pituitary gland is essential for pregnancy sustained through activation of corpus luteum 
which in turn causes production of progesterone161. The mid-cycle luteinization surge is 
known to play a crucial role in the development of the oocyte and the follicularization 
process. However, recent studies indicate that the abnormal level of LH may be 
detrimental to the embryo development. In addition, the reduction in concentrations of 
human LH in the follicular fluid can cause decreased production of follicle-stimulating 
hormones (FSH). This study supports the hypothesis that decreased concentrations of 
LH can affect the quality of oocytes159. 
Serine was positively associated with pregnancy along with threonine in platelet 
poor plasma. Valine, glycine, serine, and threonine concentrations in plasma were closely 
correlated with insulin resistance and obesity. In addition, a significant positive 
association of lactate and leucine concentrations with insulin resistance was observed 
regardless of obesity. Notably, significant decreases in serine and threonine 
concentration were observed in obese women with PCOS and patients with insulin 
resistance compared to non-obese PCOS patients and patients with normal insulin 
sensitivity, suggesting opposing effects of PCOS and their two common features on 
serine and threonine metabolism162. An earlier study on obese mice supplemented with 
threonine for 10 weeks showed weight reduction and improvement of insulin 
resistance163.  In addition, a cross-sectional study evaluating the association of amino 
acids regarding insulin sensitivity in men showed a significant association between serine 
concentration and insulin sensitivity improvement164. 
In summation, our findings here of lipid species being correlated with 2PN values 
provides a basis for the detrimental effects of high BMI, and the lipid disruptions that 
accompany this physical state, on embryo quality and success of clinical pregnancy. 
Group II ovulatory disorders compose ~85% of all ovulation disorders and are caused by 
conditions such as abnormal BMI. Obesity is known to result in disruptions to endocrine 
and paracrine mechanisms such as insulin signaling, which is evinced to act on the HPO 
axis and can lead to adverse pregnancy outcomes.   
Limitations with this analysis included a small cohort size, which carried the risk of 
overfitting our regression estimates. Standardization of the regression coefficients aided 
us in overcoming this challenge, and reliance on adjusted R-squared as a performance 
metric meant that our measures were adjusted to produce unbiased estimators of the 
population and effect. Relative quantification165 of circulating lipids and metabolites 
enabled us to determine the specific species that were correlated with the number of 
distinct pronuclei and two polar bodies (2PN) or embryo quality, molecules correlated with 
BMI, and putative markers for successful pregnancies following IVF.  
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Supplementary appendix:  
1. Plasma data: 
a. BMI 
Variable selected Prob> |t| Model R2 and R2 adj 
BMI and lipids with glycerophospholipids 
LPC (18:1) 0.0133 R2 = 0.839 
R2 adj= 0.785 








BMI and lipids without glycerophospholipids 
CE (18:0) 0.0014 R2 = 0.794 
R2  adj= 0.726 
Root mean square error= 
0.156 
CE (20:3) 0.0015 
CE (22:4) <.0001 
FA (14:1) <.0001 
FA (17:1) 0.0005 
Heptadecanoic acid 0.0089 
BMI and metabolite model 
2-hydroxyglutaric acid 0.0189 R2 = 0.804 
R2  adj= 0.739 




Malic acid 0.0349 
serine <.0001 
tyrosine 0.0157 
BMI and clinical parameter model 
Fasting glucose 0.3374 R2 = 0.807 
R2  adj= 0.768 
Fasting Insulin <.0001 
Total score Block food Fat screener 23 high 0.0054 
Average Sitting Total Minutes/day 0.1554 
Final plasma BMI model 
LPC (18:1) 0.0244 R2 = 0.856 
R2  adj= 0.818 
PC (16:0-22:4) 0.0044 
PC (16:1-22:6) 0.0594 
Malic acid 0.0239 




Variable selected Prob> |t| Model R2  and R2  adj 
2PN and Lipids with glycerophospholipids 
LPC(22:6) 0.0213 R2 = 0.805 







PE-P (16:0-22:6) 0.0004 
2PN and Lipids without glycerophospholipids 
CE(22:6) 0.00066 R2 = 0.799 
R2  adj= 0.666 
Lauric acid 0.01373 
CE (20:5) 0.02362 
FA(19:1) 0.02885 
CE(16:0) 0.06641 
Myristic acid 0.06739 
CE(14:0) 0.11267 
FA (20:5) 0.14690 
FA (18:2) 0.38866 
FA (14:1) 0.59931 
2PN and metabolite model 
2-ketoisovaleric acid 0.0001 R2 =  0.829 
R2  adj= 0.749 
3-aminoisobutyric acid 0.0004 
Aspartic acid 0.0236 
Beta alanine 0.0007 




2PN and clinical parameter model 
Female age (yr) 0.4979 R2 = 0.623 
Fasting glucose 0.1282 R2  adj= 0.445 
Fasting insulin 0.9776 
Mediterranean diet score 0.1929 
Total score Block food Fat screener 23 high. 0.8744 
Total score Block food questionnaire fruit 
vegetable screener 11 low. 
0.0712 
Average Sitting Total Minutes day 0.0221 
Total cumulative FSH used 0.0015 
Final plasma 2PN model tested for clinical parameter (Exclude the clinical parameter) 
LPC (22:6) 0.0057 R2 = 0.792 
R2  adj= 0.726 
LPE (20:4) 0.0023 
PC(14:0-16:1) 0.0329 
CE (16:0) 0.0056 
FA (20:5) 0.0212 
phosphate 0.0003 
  
2. Follicular fluid: 
a. BMI  
Variable selected Prob> |t| Model R2  and R2  adj 
BMI and with glycerophospholipids 
LPC(18:2) 0.0061 R2 = 0.839 
R2  adj= 0.797 
  
LPC (20:2.) 0.0280 
LPC(o-18:1) 0.0006 
PC (20:3-20:4) 0.0003 
PE-P(16:0-22:6) <.0001 
BMI and without glycerophospholipids 
CE (16:0) 0.0236 R2 = 0.779 
R2  adj=  0.705 
CE (18:3) 0.0004 
CE(20:3) <.0001 
FA (18:1) 0.0009 
FA(19:0) 0.0028 
FA(22:2) 0.0239 
BMI and metabolite model 
Aspartic acid 0.0003 R2 = 0.795 
R2  adj= 0.754 
histidine 0.0285 
Indole-3-propionic acid 0.0008 
tyrosine <.0001 
Final BMI model 
PE-P(16:0-22:6) 0.0040 R2 = 0.880 
R2  adj= 0.856 
Aspartic acid 0.0141 
Indole-3-propionic acid <.0001 
Fasting insulin <.0001 
  
b. 2PN: 
Variable selected Prob> |t| Model R2  and R2  adj 
2PN and with glycerophospholipids 
Acylcarnitine (C16:0) 0.0033 R2 = 0.833 
R2  adj= 0.755 
  
Acylcarnitine C18:1 0.0358 
LPC (16:1) 0.0047 
LPC (22:4) 0.0028 
LPE (20:4) 0.0042 
LPI (18:1) 0.0048 
LPI (18:2) 0.0023 
PC-P(18:0-22:6) 0.0013 
2PN and without glycerophospholipids 
CE (16:1) 0.0517 R2 = 0.813 
R2  adj= 0.725 
CE (18:1) 0.0009 
CE (18:3) 0.0732 
CE (22:6) 0.0003 
FA (14:0) 0.0410 
FA (16:0) 0.0404 
2PN and metabolite model 
1-monoolein 0.0834 R2 = 0.794 
R2  adj= 0.729 





Final 2PN model tested for clinical parameter 
LPE (20:4) 0.0040 R2 = 0.808 
R2  adj= 0.747 
PC-P(18:0-22:6) 0.0115 
2-aminobutyric acid 0.0934 
alanine 0.0062 
phenylethylamine 0.0564 
FA (22:3) 0.0438 
 
 
  
